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ABSTRACT 
Tuberculosis (TB) causes more than 1.2 million deaths each year globally.  Yet, survivors of 
tuberculosis are left with long term sequelae of chronic inflammatory responses with 
consequent reduced quality of life. Biomarkers of monitoring tuberculosis disease activity, 
clinical response and mortality might assist in reducing mortality and ultimately in improving 
quality of life post tuberculosis disease.  
The general aim of the thesis was to describe mortality among patients treated for a first 
episode of tuberculosis in Tanzania in relation to selected known pathogen related predictors 
of poor tuberculosis outcomes, namely HIV and anti-tuberculosis drug resistance. We also 
explored the role of cytokines as part of the host immune response, in relation to mortality 
and in modulating lung damage. 
In Paper I: We show an overall mortality of 3.4 – 9.3% among patients treated for 
tuberculosis in Tanzania, and that TB/HIV patients were at a higher risk of death compared to 
TB mono-infected patients. The best benefits of antiretroviral therapy (ART) in reducing 
mortality for TB/HIV co-infected patients occurred when ART was initiated after 14 days of 
anti-tuberculosis therapy (ATT). We also observed (Paper II) that among 861 patients with 
tuberculosis, those with isoniazid resistance without concomitant rifampicin resistance had an 
increased risk of unsuccessful treatment outcome (death or treatment failure or loss from 
follow up - combined). In Paper III, we observed that patients who exhibited, in cell-based 
assays, higher interferon gamma (IFN-γ) responses against cytomegalovirus (CMV), Epstein 
Barr virus (EBV) or Mycobacterium tuberculosis ESAT-6 antigens at the time of TB 
diagnosis had a survival benefit following treatment for TB. However, IFN- γ responses to 
some viral antigens (H5N1 and HSV-1) as well as other mycobacterial antigens (Ag85A, 
Rv2958c, Rv0447c) were not significantly different between patients who survived and those 
who died. In Paper IV, we observed very high levels of interleukin 6 (IL-6) in serum from 
234 patients with pulmonary tuberculosis, as compared to levels of IL-6 in serum from seven 
healthy controls.  Other cytokines (IFN-γ, TNF-α, IL-2, IL-10, IL-17A and IL-21) were also 
analyzed at the time of TB diagnosis. Unlike with the other cytokines which returned to 
pretreatment levels or below following ATT, IL-6 levels at end of ATT were significantly 
higher than their corresponding pre-treatment levels. In addition, we also found that higher 
IL-6 levels at TB diagnosis correlated with survival of patients with pulmonary tuberculosis, 
as well as with severe lung injury, defined by chest x-ray score more than 80 at diagnosis.  
In conclusion, between 3 and 9 out of 100 Tanzanian patients treated for first time 
tuberculosis will die during treatment. Well planned ART, appropriate clinical monitoring 
and timely addressing of background isoniazid resistance are essential to improve treatment 
outcomes. While anti CMV and EBV immune responses may serve to stratify mortality risk, 
adjunct therapy with IL-6 may serve as a possible target in reducing lung damage and 
consequently aid to improve quality of life following Mycobacterium tuberculosis disease in 
the future. 
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1 INTRODUCTION 
“…She is my only child and a mother of a 5 year old child. Will she survive or die? I need 
her, for I have nothing to offer to the child….”A voice of a crying woman very early on a 
Monday morning keeps echoing in my mind as one of the very many cases physicians in 
Tanzania encounter. This is a vivid image of many years from which I find reason, 
enthusiasm and strength to carry on with research in infectious diseases - particularly, 
tuberculosis (TB) and human immunodeficiency virus (HIV) infection. The question posed 
by the sorrowful mother is a difficult one, which unequivocally demands an answer.  At this 
juncture, we are able to provide patient prognosis largely based on clinical and 
epidemiological evidence – which is associated with a high level of credibility. Nevertheless, 
enough patients succumb to TB even in the absence of known predictors of bad outcomes 
such as HIV co-infection and/or multidrug resistance. In Tanzania, routinely collected TB 
reports show that 90% of patients newly treated for TB in Tanzania will be cured while about 
6% will die during therapy 
1
.  Every life counts – therefore, there is an urgent need to describe 
and characterize factors that could provide clues to so many unanswered questions in clinical 
TB. These answers may also aid in reducing mortality by addressing hitherto unknown 
factors – so we may one day say to such a grieving mother with great certainty that no one 
dies of TB or at least, very rarely in our setting! If patients with TB survive, the final outcome 
may not necessarily be all too positive; 74% of them will develop clinical features of chronic 
lung disease in the last month of their TB treatment 
2
.  Yet, in HIV-infected individuals, a 
previous episode of TB increases the risk of another TB episode and death 
3, 4
. Healthcare 
researchers and practitioners therefore have the obligation to learn how to minimize both the 
death toll as well as lung damage in patients with TB. In this thesis, we explore factors that 
could be linked with survival and lung damage in patients with TB, paving the way in search 
of better tools to improve survival as well as quality of life for patients with TB in Tanzania 
and internationally.  
1.1 TUBERCULOSIS 
1.1.1 Etiology and pathogenesis 
Tuberculosis (TB) is a deadly disease affecting millions of people, and is caused by the 
bacterial pathogen Mycobacterium tuberculosis (M.tb), which was first described by Robert 
Koch in 1882 
5
. The infection is transmitted through aerosol droplets from an infected 
individual by coughing, sneezing, singing or mere talking 
6-8
.  However, it appears that cough 
is most effective in transmitting the bacteria, not only due to the number of infectious 
particles expelled, but largely due to the small size of the droplets, which are persistently 
suspended in air 
6-8
. Transmission risk is affected by contagiousness of the source (infected 
person), usually determined by the M.tb load in sputum and the proximity between the source 
and other individuals 
9
. The extent of TB disease in the lung - which in turn increases the 
frequency of coughing – also greatly affects transmission dynamics, alongside the afore-
mentioned factors 
8, 9
. In this regard, public health strategies to reducing TB must continue to 
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address improved living conditions and early case detection and treatment 
10
.  Limiting the 
extent of pulmonary TB disease by reducing host lung tissue damage using adjunct therapies 
might also be mutually beneficial to achieve a reduction in lung damage and therefore 
transmission dynamics. 
Inhaled M.tb droplets will be transported to the respiratory bronchioles where they will be 
phagocytosed by alveolar macrophages residing in the lower and middle lung zones 
11-13
. 
Effective containment of M.tb by the host’s immune system establishes a latent infection, 
termed as latent TB infection (LTBI) as opposed to M.tb propagation in the host leading to 
clinical disease (active TB). Therefore, deficiency in innate immune function 
14
 and/or 
adaptive immunity heavily compromises control of M.tb infection, fosters infection 
transmission, and increasing possibilities to succumbing to the disease 
15
. Acquired 
immunodeficiency due to HIV co-infection is a major contributor to TB-related deaths, and 
presents an important clinical setting to study immune cell interactions in TB disease 
16, 17
. 
The hallmark of TB pathogenesis lays in the initiation; maturation and maintenance of 
granuloma as a result of the interplay between innate and adaptive immunity 
18
.  Neutrophils 
are engaged very early on. Activated by M.tb products, neutrophils are responsible for the 
recruitment of leucocytes and promotion of the inflammatory process. T helper 1 (Th-1) 
response of the adaptive immunity is central to the formation and maturation of the 
granuloma 
19
. The typical TB granuloma, as seen in figure 1, has central caseous necrosis 
surrounded by different types of macrophages; (epithelioid, multinucleated - Langhans, 
foamy) all encircled with a layer of lymphocytes 
18, 19
.  In non-human primates (NHP) TB 
granuloma formation has been shown to begin at the hilar lymph nodes after three weeks of 
infection thereafter involving the regional thoracic lymph nodes and subsequently the lungs 
approximately four to six weeks following infection 
20
.  
Figure 1: A. Granuloma architecture from tissue histological section (Source:  Gil el al PlosOne 2010) 
B. Schematic cellular representation of TB granuloma (Source: Guiradoe et al 2013) both images are taken from 
reference 18  
Disruption of the granuloma results into cavity formation in lungs. Consequently, TB lesions 
observed is a mixture of inflammatory and tissue healing processes characterized by mixed 
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immuno-physiological features such as; consolidation, calcification, cavity formation and 
fibrosis, as well as immune cell infiltrates comprising lymphocytes and myelocytic cells 
20
. 
Although TB primarily affects the lungs, M.tb can disseminate through the lymphatics to the 
rest of the body 
20, 21
.   
1.1.2 Global epidemiology of tuberculosis 
It is estimated that about 1.7 – 1.9 billion people worldwide harbour LTBI 22-24.  The recent 
global burden of disease estimates that latent tuberculosis is the second most prevalent 
infection globally, responsible for 1 out of 4 years lived with disability (YLD) in 2016 
24
. In 
general, 10% of individuals with LTBI will develop TB disease at some point in their lifetime 
25
; the risk is higher in HIV co-infected persons and other in immunosuppressive scenarios 
such as cancer, transplantation and diabetes 
26, 27
. Males carry a disproportionately larger 
burden of TB disease, and are presumptively the source for propagating the infection 
28, 29
.  
According to global statistics, it is estimated that in 2015 there were 10.4 million new patients 
who developed TB 
23
. More than 80% of these cases are in 30 countries classified as high 
burden TB countries, mainly in Sub-Saharan Africa (including Tanzania) and Eastern 
Europe, South East Asia and China 
23
. The estimated global TB burden is represented on 
figure 2 
23
.  
Figure 2: Esimated global tuberculosis incidence rate 2015 (Source: The WHO - global tuberculosis report 
2016)23   
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Drug-resistant TB, largely comprising multidrug resistance (MDR-TB) and extensive drug 
resistance (XDR-TB) in addition to HIV co-infection are the major drivers of the global TB 
epidemic as well as severe TB disease and increased mortality 
23, 24, 30
. MDR-TB is defined as 
resistance to at least isoniazid (INH) and rifampicin (RIF) 
31
, while XDR-TB is defined as 
resistance to INH, RIF and any fluoroquinolone i.e. moxifloxacin, levofloxacin, gatifloxacin 
and at least one of three injectable second-line drugs i.e. kanamycin, capreomycin and 
amikacin 
31
. The global prevalence of MDR-TB is estimated to be 3.3 – 3.9 % 23, 32, mainly 
centred in the South East Asia region as well as China 
23
.  
Re-occurrence of the TB epidemic coincided with the emerging of HIV epidemic in the early 
-1990s 
26
. Globally, there were approximately 0.5 million HIV-infected individuals with TB 
reported by the World Health Organisation (WHO) in 2016, while circa 15% of notified TB 
patients who underwent HIV testing had HIV co-infection 
23
. As depicted in figure 3, the 
prevalence of HIV among patients with TB has the highest impact in Sub-Saharan Africa 
(SSA) where about 80% of TB/HIV cases are usually reported 
23
. In 2015, the prevalence of 
TB/HIV co-infection was 36% in the SSA region, particularly high in South Africa 
23, 24
. 
Only 58% of the estimated MDR-TB cases are treated, while only 55% of all reported TB 
cases in 2015 had an HIV test with even fewer patients receiving Antiretroviral Therapy 
(ART) 
23
. Missed opportunities for treatment such as these should be minimised as we get 
closer to ending TB by 2030 
33
.  
 
Figure 3: Estimated HIV prevalence among patients with tuberculosis in 2015 (Source: The WHO - 
Global tuberculosis report 2016)23 
In 2015,  a total of 1.2 million deaths were due to TB; the vast majority had drug-sensitive 
TB (1.1 Million) while MDR/XDR-TB) contributed to a further 0.1 million deaths 
30
. Figure 
4 shows the estimated global number of incident TB cases and mortality trends from 2000 to 
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2015 
23
. Multiple efforts from different stakeholders have resulted in a reduction of TB cases 
as well as mortality among tuberculosis patients (figure 4). However, the WHO estimates the 
trend of decline is inadequate to attain the anticipated goals to end tuberculosis by 2030
23
. 
 
Figure 4: Global trends of estimated incident TB cases and mortality 2000 – 2015 (Source: The 
WHO – Global TB report 2016)23 
1.1.3 Clinical manifestation of tuberculosis 
Predominantly a pulmonary disease (pulmonary TB, PTB) in adults, TB has the potential to 
spread to and affect any part of the body (extra-pulmonary TB, EPTB), and is therefore a 
systemic disease 
31, 34
. Clinical presentation of patients with TB is variable depending on the 
affected organ and immune response to the infection. In general, symptoms in PTB include 
cough, sputum production, low grade fever, night sweats, weight loss, difficulty in breathing 
and haemoptysis 
35, 36
. These symptoms are non-specific and can be present in many other 
diseases. On the other hand, it is not uncommon to find disseminated TB presenting with 
non-classical features or mere asymptomatic among immuno-compromised individuals 
37
. 
Therefore, in addition to clinical features, accurate and easy-to-use points of care TB 
diagnostics are highly necessary 
36, 38
.  
1.1.4 Diagnosis of tuberculosis 
TB diagnosis requires confirmation of the presence of M.tb. This can be achieved through 
bacteriological methods or molecular techniques such as Nucleic Acid Amplification Tests 
(NAAT) 
39
. Conventional acid fast bacilli (AFB) staining on smear microscopy is a 
commonly used methods in the clinics in resource limited setting. M.tb culture on liquid or 
solid media is the current gold standard for TB diagnosis 
39
.  Molecular methods such as line 
probe assays (LPA) or Gene Xpert MTB/RIF are instrumental in identifying both TB and 
drug resistance patterns for clinical decisions 
39-42
. The Gene Xpert MTB/RIF is an 
automated, real time Polymerase Chain Reaction (PCR) test that has revolutionized the 
diagnosis of TB and RIF resistance, thus recommended as standard of care in the context of 
high TB and HIV 
38, 43
. 
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Interferon gamma release assays (IGRAs) have been used for diagnosis of LTBI in several 
countries but are not able to distinguish between active disease and latent infection 
44
. Thus 
they may not be so useful in countries with high TB burden 
44
. Another challenge with 
IGRAs is the high variability between tests, making them rather difficult to use for diagnosis 
and/or monitoring of TB in high burden settings 
45, 46
.  
Radio imaging techniques especially X-ray have been used in the evaluation of patients with 
TB both to assist in diagnosis, gauging the extent of tissue damage and monitoring treatment 
progress by assessing tissue healing 
34
. There are various imaging features of PTB including 
combinations of consolidation, fibrosis, calcification, cavity, nodulation or fibrosis 
47
. These 
features are not pathognomonic; there are other disease/pathologies such as sarcoidosis, lung 
adenocarcinomas and chronic granulomatous disease that mimic TB features on radio-
imaging
48-50
. However, in settings of smear-negative PTB or TB osteomyelitis, plain 
radiographs have been useful 
36, 48
. Unfortunately until recently, there were no simple, 
validated tools that allowed objective comparison of radiological images between TB patients 
as well as same patient at different time points during treatment 
47
.  
Other imaging methods such as magnetic resonance imaging and computed tomography (CT-
scan) with or without positron emission tomography (PET) are essential for the diagnosis of 
EPTB 
51-53
. PET-CT and PET Magnetic Resonance Imaging (MRI) are increasingly used in 
clinical settings especially in TB of the bone and mimics of solid tumours 
51, 54
 but have also 
been used in research settings as for diagnostic evaluation and/or clinical assessment of 
cure
50, 55
. 
 
Figure 5: Chest x-ray of patient with pulmonary tuberculosis 
(Case courtesy of Dr Hani Salam, Radiopaedia.org, rID: 12437) 
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1.1.5 Tuberculosis treatment 
Assessment of anti-TB drug resistance prior to initiating treatment is essential for appropriate 
management. Treatment of drug-sensitive TB takes approximately six months, and comprises 
5mg/kg isoniazid (INH), 10mg/kg rifampicin (RIF), 25mg/kg ethambutol (E) and 15mg/kg 
pyrazinamide (Z) for 2-3 months followed with 5mg/kg isoniazid and 10mg/kg rifampicin for 
the remaining time 
56
. For re-treatment, patients are given a daily injection of streptomycin 
(15mg/kg injection) in addition to RIF, INH, Z, and E; for 2-3 months, depending on sputum 
conversion. It is therefore important to preserve the potency of isoniazid and rifampicin, 
which form the cornerstone in the treatment of drug-sensitive TB. Although treatment 
success rate globally is usually above 85% in most cases, there is a need to accelerate the 
development of new TB drugs to cater for M.tb drug resistance strains.  
The treatment of MDR-TB is complex, requiring the use of many drugs which are less potent 
and often accompanied with unpleasant side effects 
42, 57, 58
. The conventional treatment 
duration for MDR-TB is a minimum of 20 months as guided by M.tb culture conversion  
42
. 
Six to seven out of ten patients with MDR-TB will be treated successfully after 20-24 
months
23, 59
. The need for shorter and more effective treatments regimen led to the 
introduction  and inclusion of  the new anti-TB drugs Delamanid or Bedaquiline to TB drug 
regimens 
42
, which aim to achieve successful MDR-TB treatment  in 9 – 12 months.  Both 
drugs have shown faster and higher culture conversion rates, albeit with associated side 
effects e.g. arrhythmia. About 80 - 97% of patients with MDR – TB achieve negative 
cultures, within six months of treatment with Delamanid or Bedaquiline 
60, 61
. 
1.2 CYTOKINES PLAY KEY ROLE IN MEDIATING IMMUNE RESPONSE TO M. 
tuberculosis 
The success of M.tb to establish infection depends on its ability to multiply within the 
alveolar macrophages and disseminate by counter-acting the host response to control its 
propagation
11, 12, 20, 62
. Cytokines are soluble substances that mediate the cross talk between 
immune cells as well as between non-immune cells, and play an important role in relation to 
host control of TB through enhanced macrophage as well as lymphocyte activity and 
granuloma formation 
14, 63
 Many cytokines have been studied in relation to M.tb control; this 
interplay is complex and not completely understood, involving both the innate and adaptive 
immune cells, as depicted in figure 6  
14, 63, 64
.  Several key cytokines have a primary role in 
M.tb pathogenesis and control: interleukin 12 (IL-12), IL-18 interferon gamma (IFN-γ), 
tumour necrosis factor alpha (TNF-α), IL-1β, IL-6, IL-17 and IL-2, as observed in animal 
models of TB and very importantly in patients with TB 
62, 65, 66
. 
 14 
 
Figure 6: Interaction of the innate and T helper 1 cytokines following exposure with 
Mycobacteria tuberculosis infection (Source: Cooper Mucosal Immunol, 2011)14 
The interaction between M.tb and macrophages induces a series of events leading to 
production of IL-12 and IL-18 
67-70
. IL-12 is important for the activation of immature 
dendritic cells as antigen presenting cells (APCs), which will be prompted to translocate from 
the site of infection to the regional lymph nodes to present M.tb antigens to T cells, priming 
of the adaptive immune response 
66
. Priming of CD4+ T helper cell response follows antigen 
presentation in mediastinal lymph nodes about 10-14 days after the infection 
20, 71
. Cytokines 
resulting from T helper 1 (Th1) pro-inflammatory responses, IFN-γ, TNF-α, IL-2 and 
possibly IL-17, in some cellular subsets are crucial in host defence against M.tb 
66, 72-74
. 
IFN-γ is produced by activated CD4+ and CD8+ T cells and natural killer (NK) cells, and is 
important to enhance intracellular killing of M.tb by macrophages and dendritic cells – which 
also leads to antigen processing, presentation and augmentation of T-cell activation 
75
. 
Deficiencies in the IFN-γ pathway are associated with failure to control M.tb infection, 
exaggerated tissue necrosis and death 
15, 75, 76
. IFN-γ responses to specific pathogenic M.tb 
antigens has been utilised in the clinical diagnosis of LTBI in low incidence settings. 
However, its clinical utility as a diagnostic tool for active TB or gauge clinical response 
remains to be determined 
46, 77
.    
During M.tb infection, TNF-α is produced initially by monocyte-derived cells, and later by T 
and NK cells following activation 
65, 78
. Together with IFN-γ, TNF-α potentiates macrophage 
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phagocytic activity to engulf M.tb bacilli and promote apoptosis, which also amplifies the 
adaptive immune response signals 
79
. TNF-α is also important in promoting neutrophil 
aggregation and is essential for the formation and maintenance of effective granulomas 
65
. A 
fine-tuned balance of TNF-α function is important in modulating TB pathology. Higher levels 
of TNF-α have been shown to correlate with severe lung pathology 80, 81. Alternatively, TNF-
α blockade perpetrated increase in M.tb load, severe lung necrosis as well as early death in 
mice 
81
 and TB reactivation in humans 
82
.  Interesting still, good clinical responses to anti 
tuberculosis therapy (ATT) is associated with reduction in TNF-α levels 73.  In patients 
treated with anti-TNF-α who eventually develop TB, sudden discontinuation of anti-TNF-α 
therapy may be associated with severe exacerbation and further lung destruction 
83
. Taken 
together, TNF-α is an important mediator in TB pathogenesis and its function needs to be 
well regulated for desirable clinical outcomes. 
IL-1β has also been shown to be important in M.tb infection 14, 81, 84. The mechanism of IL-
1β-mediated effects in TB pathogenesis is not very clear; however signalling via toll like 
receptors (TLR) in conjunction with IL-1β production and activation of the adaptor molecule 
MyD88 
84
 has been shown in TB. IL-1β is important in recruiting perivascular phagocytes 
and promoting inflammation and granuloma formation 
85
. Mice lacking IL-1β showed 
inability to produce IL-12 and TNF; these mice had severe lung disease and died despite a 
well preserved adaptive immune response 
81
. Host-directed therapy targeting IL-1β has been 
proposed in TB, which reflects the dual nature of this cytokine in maintaining immunological 
balance in disease 
86
. 
The importance of IL-17 in TB has been noted in its ability to promote quick trafficking of 
memory CD4+ T cells from lymph nodes into the lungs for early M.tb control 
87
, In NHP 
model of human TB, animals that are able to control TB showed up regulation of IL-17 
pathway genes
88
. Similarly, whole blood levels of IL-17 were lower among children with TB 
compared to healthy controls 
89
.  
Pleiotropic cytokine such as IL-10 and IL-6 are important in modulating the severity of TB 
disease but simultaneously allow enough pro-inflammatory activity for successful TB 
control
64
. Elevated levels of IL-10 is documented in both lung and serum of patients with TB; 
however its correlation with clinical presentation or outcome is variable 
90
.  Levels of IL 10 
were significantly higher in children with TB disease compared to healthy individuals 
89
. It 
seems plausible that some anti-inflammatory effect of IL-10 is necessary in order to eradicate 
M.tb in the granuloma 
64
, since a generally requirement for pro-inflammatory activity exists
91
.  
IL-6 is a pleiotropic cytokine with both pro- and anti-inflammatory effects that is produced 
by many cell types including monocytes, macrophages, dendritic cells, mesenchymal stromal 
cells and fibroblasts 
92, 93
.  Patients with active TB have higher levels of IL- 6 compared to 
healthy controls, and their IL-6 quantities directly correlated with systemic disease, 
mycobacterial load in sputum and lung injury 
80
. IL-6 signals via its receptor, IL-6R in 
association with gp130, both of which are expressed on T and B cells, hepatocytes and 
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fibroblasts among others.  IL6R-bound IL-6 can also promote trans-signalling, whereby the 
IL-6-IL6R complex would bind to gp130 on cells to initiate signalling. IL-6 signalling 
induces the release of several liver proteins, T-cell differentiation, B-cell activation and 
antibody production, secretion of vascular endothelial growth factor (VEGF), platelet 
generation and collagen production among others
92
. 
Preclinical studies indicate that IL6 may be important for survival during TB disease. Mice 
deficient for IL-6 succumbed to M.tb but not to M. bovis BCG challenge 
30
. In one study it 
was reported that M.tb induces IL-6 to inhibit macrophage response to IFN-γ and thereby 
dampen the adaptive immunity 
94
. Blocking IL-6 trans-signalling did not affect protection in 
M.tb-infected mice but is associated with control of inflammation 
23
. However, complete 
blocking the IL-6R would reactivate latent TB 
83
. Thus, abrogation of cytokine production 
from the start cannot be an option but rather modulation of their dynamics during disease. 
Since M.tb infection presents with a wide spectrum of disease (latent vs active; early active 
disease vs late), cytokine secretion may vary accordingly and studies in mice can’t directly be 
translated to humans. Further clinical investigation among humans with TB is warranted to 
unfold the role of IL-6, and whether anti-IL-6/IL-6R therapies may be beneficial to reduce 
lung damage, manage  immune reconstitution inflammatory syndrome (IRIS) in patients with 
or without HIV and optimizing MDR/XDR-TB treatment outcomes 
80, 95
. It is evident that 
cytokines play key role in TB pathogenesis, but their role of as markers of disease severity 
and/or clinical response is yet to be precisely elucidated 
46, 77
. 
1.3 TUBERCULOSIS AND HIV/AIDS CO-INFECTION PRESENT CLINICAL 
MANAGEMENT CHALLENGE 
The burden of TB among HIV-infected individuals is high; up to 40% of HIV-infected 
individuals developed TB in the SSA region 
96, 97
. Despite these high TB rates, 30 – 50% of 
TB cases are diagnosed post mortem 
97-100
. HIV-infected individuals are at an increased risk 
for TB, exhibiting both true relapse and re-infection presenting with mixed M.tb strains 
101
. 
HIV mainly infects CD4+ T cells, dendritic cells and macrophages 
102
, resulting in impaired 
control of infections such as M.tb due to quantitative and qualitative dysfunction of the 
macrophage and CD4+ T-cell responses 
16
. Chetty and colleagues demonstrated that HIV/TB 
co-infected individuals produce less CD4+ and CD8+ T-cell specific cytokines compared to 
HIV mono-infected individuals suggesting that the impaired immune function could be the 
cause for inability to control M.tb 
103
.  On the other hand, impaired control of M.tb among 
HIV-infected individuals, who are antiretroviral therapy (ART) naïve, has been associated 
with immune cell exhaustion and autophagy 
104, 105
. CD4+ T cells from patients with HIV/TB 
have been shown to express markers of cell exhaustion (T-cell immunoglobulin and mucin 
domain 3 (TIM3) and programmed cell death 1 (PD-1)) and exhibited reduced control of 
M.tb infection compared to T cells from healthy controls; this phenomenon was reversed with 
blockade of TIM3/PD1 
104
.  HIV-infected macrophages demonstrate increased IL-10 
production and inhibition of apoptosis
17
 which is restored with early ART 
16
. Overall the 
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number of incident TB cases has an inverse relationship as the duration of ART increases 
after initial immune reconstitution phase 
4, 106, 107
.   
Diagnosis of TB among HIV-infected individuals presents an enormous challenge to 
clinicians, often exhibiting atypical symptoms and negative microbiological and imaging 
results 
37, 108
. The invention of Xpert MTB/RIF has improved TB case detection compared to 
smear microscopy, with detection rates increased by up 60% among patients with smear 
negative TB 
109, 110
. Yet, about 48% of smear-negative TB/HIV patients will be missed by 
Xpert MTB/RIF system 
110
. This unmet gap calls for urgent invention of rapid and more 
sensitive diagnostic protocols.  
HIV and TB co-infection also presents challenges during treatment. Treatment of HIV-
infected individuals with ART demands careful planning for patients with TB co-infection. 
Concomitant administration of ATT and ART often results in unwanted drug interactions, 
increased toxicity and IRIS 
111, 112
. RIF, a key first line anti-TB drug, reduces serum 
concentration of most non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase 
inhibitors as well protease inhibitors (PIs) 
113-117
. Serum levels of nevirapine and rilpivirine 
are greatly reduced to sub-therapeutic levels, so the combination of any of these NNRTIs is 
usually avoided in combined ATT and ART 
114, 117
.  Another anti-retroviral drug, efavirenz is 
affected to a lesser extent than nevirapine, therefore dose adjustment greater than 600mg 
daily is not usually recommended in general practice 
118-120
. Rifabutin is a rifamycin of choice 
for patients with TB/HIV co-infection when PIs are considered 
121
; however, efavirenz is 
expensive and not available in low-income countries where TB/HIV burden is high. In 
contrast, ritonavir-boosted PI decreases rifabutin to sub-therapeutic levels, necessitating dose 
adjustment to 150mg daily when the combination is prescribed 
121
. Availability of newer anti-
TB drugs such as delamanid provides a broader avenue for choice with fewer drug 
interactions yet good treatment outcomes although access may be a another challenge in 
resource-limited areas 
122
. 
Scale-up of ART in the SSA region has tremendously improved survival of patients with or 
without TB 
123
. However, despite the gains, the risk of TB is highest during the immune 
reconstitution phase of ART usually the first three to six months of ART and decreases 
thereafter 
106
. Multiple reasons therefore contribute to less successful treatment outcomes 
among TB/HIV co-infected individuals compared to individuals with TB. Therefore, HIV co-
infection is often a mandatory component which needs to be accounted for in TB research 
and clinical practice.  
1.4 ISONIAZID IN THE TREATMENT AND PREVENTION OF TUBERCULOSIS 
Isoniazid is a potent anti-TB drug with early bactericidal effect 
124, 125
. As a first line drug of 
choice, INH in combination with RIF is used in standardised regimens to shorten treatment 
duration of drug-sensitive TB 
56
. In addition, INH is recommended as standard of care for TB 
prophylaxis among recent tuberculin skin test (TST) converters (with or without history of 
close TB contact), children who are contacts of patients with PTB or HIV infected individuals 
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after exclusion of active TB disease 
38, 126, 127
. Indeed, INH prevention therapy (IPT) is one of 
the three pillars of TB prevention in addition to intensified case finding and infection 
control
33
. 
The benefit of IPT in preventing mortality and reducing TB occurrence and recurrence 
among HIV patients is well established in the presence or absence of ART 
128-130
. However, 
there are some practical uncertainties that need to be sorted out: the ideal duration of IPT for 
HIV infected individuals, exclusion of active TB among HIV infected individuals in 
resource-limited settings, sub-optimal compliance to IPT treatment and possibilities of 
emerging resistance in the long term 
131-134
. Compliance to IPT is necessary to prevent 
mortality 
135
. Variable non-compliance rates have been shown, ranging from 2 – 36% for 6 
months IPT
136-140
. Worse compliance has been reported among female sex workers, among 
whom IPT non completion rate was 61% 
141
. These challenges therefore present impediments 
to the proposed benefits of continuous IPT for HIV-infected individuals 
129
, more so when 
resistance to INH has been linked to non-compliance 
142
.  
INH resistance is the most common type of resistance among anti-TB drugs in clinical use
32, 
143, 144
. Globally, INH resistance does not show a decreasing pattern like that seen among 
patients with MDR-TB in the United States 
142
. The median global prevalence of INH 
resistance is 13% but rates as high as 60% have been reported in some countries 
32, 143
. 
Mathematical models predict increased INH resistance when community-wide IPT programs 
are accounted for 
132, 145
.  
There are variable treatment combinations to manage INH-resistant TB, in some settings, the 
treatment of choice is left to the discretion of the clinician based on drug susceptibility testing 
(DST)
146, 147
. The WHO recommends using the RIF, Z and E regimen for 6–9 months 127. 
Treatment of patients with non-MDR INH resistance shows variable outcomes. Some reports 
show similar success rates compared to drug-susceptible TB 
148-150
, while others show less 
favourable outcomes 
146, 147, 151
.  It is therefore essential to monitor INH resistance rates so as 
to provide evidence for programmatic decision-making for preserving drug efficacy. 
Notwithstanding high resistance rates for INH, standardised regimens for treating INH mono-
resistant TB need better optimisation. 
1.5 HOST-DIRECTED THERAPIES IN TUBERCULOSIS  
 Host immune responses are immensely responsible for disease progression as well as 
severity of lung damage in patients with TB 
12
. Modulation of the host response to M.tb 
infection and during TB disease forms the mainstay of host-directed therapies against TB 
152, 
153
. These approaches are designed as adjunctive therapies to current anti-TB drug regimens 
to reduce the extent of tissue damage and improve treatment outcomes 
152-154
. Safe and 
efficacious interventions have been shown for drug-susceptible as well as MDR/XDR-TB 
83, 
154
; larger clinical trials for optimization as well as to provide newer options are needed for 
drug sensitive and drug resistant TB.  Therefore, a further understanding of the immune 
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correlates of severe lung injury and poor outcomes would be important to better understand 
TB pathogenesis, paving way for better therapies. 
1.6 TUBERCULOSIS IN TANZANIA 
Tanzania is one of the high burden TB countries according to global statistics 
23, 30
. TB 
prevalence in Tanzania is estimated to be 249 – 293 per 100 000 adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
and the most affected population groups are the elderly, adult males and inhabitants of rural 
areas 
155, 156
. The distribution of TB prevalence in Tanzania is provided in Figure 7.  
 
Figure 7: Prevalence of TB in Tanzania by cluster (Source: National Tuberculosis and Leprosy Program - The first 
National tuberculosis prevalence survey in United Republic of Tanzania final report – Ministry of Health and Social Welfare)  
Country notification for all forms of TB in Tanzania for the year 2014 was 63,151 
1
. This 
number translates to a TB case notification of 142 per 100,000 population and 48% case 
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detection rate compared to the estimated prevalence 
1, 29
. Increasing age is a strong correlate 
of TB at population level 
29
; however, TB cases among the elderly are disproportionately less 
notified in the health system (Figure 8) 
1, 155
. 
In Tanzania, all patients with TB are provided access to HIV testing services with the 
possibility to refuse. The HIV screening acceptance rate among TB patients was 88% in 
2014.  Among those tested for HIV, 19890 (36%) had TB/HIV co-infection and 87% of the 
identified TB/HIV patients started on ART within the first three months of diagnosis 
1
.  
The national prevalence of HIV among Tanzanian adults (15 – 49 years) is 5.1%. The 
proportion of HIV-positivity is slightly higher in urban (7.2%) than rural (4.3%) areas, and 
among women (6.2%) compared to males (3.8%)  
157
. Until 2016, a total of 894,356 people 
(children and adults) living with HIV (PLHIV) were receiving ART 
158
. Due to the increased 
risk for TB among PLHIV, HIV clinics are important entry points to TB care and vice versa; 
in Tanzania. TB screening is done using a simple symptom-based tool followed by detailed 
investigation whenever TB is suspected 
35, 36
. For TB prevention among PLHIV, IPT is 
provided at 300 mg dose daily for six months 
36
. 
 
Figure 8: Age distribution of Tuberculosis notifications in Tanzania (Source: National Tuberculosis and 
Leprosy Program Annual report for 2014) 
Drug-resistant TB is less common in Tanzania, presenting in the range of 0.2 – 1% and 4% 
for new and retreatment patients respectively 
159
. The national health system, however, 
reported 142 patients with MDR-TB in 2014 
1
. Based on the national survey, about 631 new 
TB patients presumably have MDR-TB (1% of 63,151 patients with TB notified in 2014) 
159
. 
Therefore, the majority of patients with MDR-TB in Tanzania may die before diagnosis. 
Increasing the access to rapid molecular diagnostic tools may improve detection of MDR-TB 
cases in the country.  
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Diagnosis of TB in Tanzania is mainly achieved by microscopy at primary health centres. 
Recent reports show that microscopy services are available in 945 facilities across the country1.  
Regional referral facilities and several district facilities provided total of 67 Gene Xpert 
MTB/RIF services in the country in 2015 (compared to 3,500 facilities health facilities 
treating patients with TB) 
1, 160
. Zonal and national referral laboratories offer culture and 
molecular technology platforms such as LPA and Gene Xpert MTB/RIF 
160
.  
Tanzania adheres to the WHO treatment guidelines for the clinical management TB 
36, 41, 42
. 
Treatment is supervised via directly observed therapy (DOT). Patients have two options to 
choose from: facility DOT, which is observed by healthcare workers at the nearest clinic 
daily or community DOT, which is supervised by a pre-identified treatment supporter at the 
patient’s residence 36, 161.  Patients on community DOT have been shown to have an ATT 
adherence rate of 96%, and in the initial assessment community DOT had similar cure rates 
but higher treatment success compared to facility DOT 
162
. The treatment success for smear-
positive TB  in Tanzania is about 90%, and overall 3,650 (5.6%) patients with of all forms of 
TB notified  in 2013, died at some point during the treatment period 
1
.  Further analysis aimed 
at improving treatment outcome is of prime importance to save approximately 4000 patients 
with TB estimated to die per year in Tanzania.  
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2 AIMS OF THE THESIS 
The general aim of this thesis was to understand further how host immune responses and 
pathogen factors influence treatment outcomes of patients treated for pulmonary tuberculosis 
in Tanzania. We explored selected host responses (unstimulated and stimulated cytokine 
dynamics) as well as pathogen factors (HIV infection, antiretroviral therapy and isoniazid 
resistant M.tb) in the hope of contributing knowledge towards reducing mortality and 
improving quality of life of patients with pulmonary TB in Tanzania. A conceptual 
framework for the thesis aims is provided in figure 9. 
2.1 SPECIFIC AIMS 
1. To quantify the mortality burden among patients initiating first line anti tuberculosis 
therapy in Tanzania (Paper I). 
2. To investigate the effect of timing of anti-retroviral initiation in relation to 
commencement of anti-tuberculosis therapy on the outcome of patients with 
tuberculosis in Tanzania (Paper I). 
3. To compare treatment outcomes among patients with and without isoniazid resistance 
in the absence of MDR-TB (Paper II).  
4. To explore baseline anti-EBV or anti-CMV interferon gamma reactivity as a predictor 
of death or survival during treatment for tuberculosis (Paper III). 
5. To explore the utility of selected serum cytokine levels as biomarkers for disease 
severity and predictor of poor treatment outcomes for patients with tuberculosis 
(Paper IV). 
 
Figure 9: Conceptual framework for the stud aims  
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3 MATERIALS AND METHODS 
Detailed descriptions of the methods used for the papers in this thesis are available in the 
respective papers a brief description is provided and summarised in table 1. 
3.1 PATIENT POPULATION 
We employed two prospective observational cohorts (cohort 1 and 2) to answer the objectives 
of the thesis as depicted in Figure 4. Eligibility into both studies included: Recently 
diagnosed pulmonary tuberculosis at one of the participating research clinics, no prior history 
of tuberculosis disease or treatment with isoniazid preventive therapy, intention to remain in 
Dar es Salaam until completion of their TB treatments.  
3.1.1  TB Cohort 1 (Paper I and II) 
Recruitment of patients for cohort 1 commenced in October 2010 and follow up was 
completed by December 2011. Patients were 15 years and older and were recruited from one 
of the participating tuberculosis clinics. We involved the 14 largest TB clinics from Ilala, 
Temeke and Kinondoni municipals in Dar es Salaam. The health facilities involved were; 
Amana, Mwanayamala and Temeke Regional referral hospitals; St Monica Modern hospital; 
Buguruni, Mnazi mmoja, Magomeni, and Sinza Health centres; Mbagala Rangitatu, Mbagala 
Kizuiani, Mbagala Tambuka reli, Tandale and Ukonga dispensaries; as well as the Infectious 
Disease Clinic (IDC) of the Muhimbili National Hospital (MNH).  
3.1.2 TB Cohort 2 (Paper III and IV) 
This cohort included patients aged 18 years and older recruited in Mwanayamala and Amana 
Hospitals and Mnazi Mmoja Health Centre between October 2013 and April 2015. We 
excluded patients known to have malignancies, or immunosuppressive therapy or those with 
end organ failure. 
3.2 TUBERCULOSIS DIAGNOSIS AND TREATMENT 
Diagnosis of tuberculosis was made by the attending clinicians according to the Tanzanian 
guidelines for diagnosis and management of tuberculosis. 
36
 Recruited patients were those 
diagnosed with pulmonary tuberculosis on the basis of sputum smear positive results. Patients 
provided spot and morning sputum samples and smears were examined for AFB using Ziehl–
Neelsen (ZN) technique by trained laboratory technicians at participating health facilities.   
All patients were managed in accordance with country guidelines 
36
. Treatment consisted of 
daily isoniazid 5mg/kg, rifampicin 10 mg/kg, ethambutol at 15 mg/kg and pyrazinamide at 
25mg/kg for 2 months (intensive phase) followed with daily 5mg/kg isoniazid and 10 mg/kg 
Rifampicin for subsequent four months (continuation phase). An additional month of 
intensive phase ATT was given in case sputum smear conversion was not attained after two 
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months of ATT. Thereafter, smear non-convertors were managed as having MDR-TB. 
Throughout duration of TB therapy, DOT was instituted.  
3.3 PATIENT RECRUITMENT AND FOLLOW UP 
Consenting patients entered into the study upon first prescription of anti-TB drugs. Interviews 
were performed by attending clinicians. In addition to routine tests, sputum and blood 
samples were requested at diagnosis. Patients were interviewed and had repeat tests 2 and 5 
months after initiation of ATT. 
3.4 LABORATORY AND CLINICAL PROCEDURES 
3.4.1 HIV infection status determination 
HIV infection was determined using Determine 
TM
 HIV-1/2 (Inverness Medical Japan Co. 
Ltd, Japan) and Uni-Gold 
TM
 HIV-1/2 (Trinity Biotech, Wicklow, Ireland) serially. Enzyme 
Linked Immunosorbent Assay (ELISA) was employed as third test for any discordance. 
3.4.2 Sputum culture for Mycobacteria tuberculosis (M. tb) complex  
Detection of M.tb was achieved in either the solid egg based Löwenstein–Jensen (LJ) or 
liquid media system, BACTEC Mycobacteria Growth Indicator Tube (MGIT) – (Beckton- 
Dickinson) according to manufacturer’s instruction.  
3.4.3 Drug Susceptibility Testing (DST) 
Drug susceptibility testing was done using the proportion method. M.tb H37Rv strain was 
used as control. The following drug concentrations were used for DST, 0.2mg/l for isoniazid, 
40 mg/L for rifampicin, 4 mg/L for streptomycin and 2 mg/L for ethambutol.  
3.4.4 Whole Blood Assay (WBA) 
Two millilitres of diluted whole blood was added into 96-well sterile culture plates pre-coated 
with: TB antigens: ESAT-6, Ag85A, Rv0447c, Rv2957, Rv2958c; common viral antigens: 
EBNA1, CMVpp65, HSV-1, H5N1, H1N1, HIV antigens: HIV env, HIV gag; and controls 
negative (RPMI) and positive (PHA). The plates were incubated 37C in a 5% CO2 incubator 
for 7 days when supernatant was transferred into non-sterile 96-well plates and frozen at -80 
C for IFN- Enzyme Linked Immunosorbent Assay (ELISA) determination later.  
3.4.5 Cytokine determination by Enzyme Linked Immunosorbent Assay  
Serum concentrations of unstimulated IFN-, TNF-α, IL-2, IL-6, IL-10, IL-17A and IL-21; as 
well as WBA-supernatant concentration of IFN- were determined using ELISA kits 
(Mabtech, Stockholm, Sweden) according to manufacturer’s instructions. Standard curve was 
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plotted and was then used to determine concentration of the cytokines based on Optical 
Density (OD) value. 
3.4.6 Chest radiographs 
Postero-anterior chest radiographs were done at entry and upon treatment completion for a 
subset of the study population in cohort 2. Radiographs were assigned scores using a 
validated tool by Ralph A and colleagues 
47
. A minimum score of zero was given where there 
were no radiographic changes while highest score of 100 was assigned when all zones in both 
lungs were affected homogenously. Presence of cavity regardless of size and number 
attracted an additional the score of 40. Consequently, the maximum score for any radiograph 
in the presence of cavities was 140.   
Definitions of chest injury:  
Severe lung damage at TB diagnosis: Chest x-ray (CXR) score equal to or above 80 (75th 
percentile) at TB diagnosis. 
Severe lung damage at TB treatment completion: CXR score equal to or above score of 50 
(75th percentile) at end of ATT. 
3.5 DATA PROCESSING  
Case record forms were used to capture demographic, clinical and laboratory data which was 
subsequently transformed to electronic data using Epi info 6 data capture screen. Analysis 
was either done by either SAS version 9.3 (paper I) or Statistical Program for Social Sciences 
(SPSS) version 23 (Paper II – IV) as summarised in table 1.   
3.6 ETHICAL CONSIDERATIONS 
This doctoral project was based on observation study involving human subjects. The project 
involved; patient interview, taking extra samples, access to the patients’ clinical information 
relating to their treatment as well as outcome.   
Ethical approval was obtained for both cohorts 1 and 2 of this thesis. Patients’ autonomy, 
rights and safety were always safeguarded. Eligible patients received information sheets with 
study details. Patients were guaranteed of appropriate health care even if they did not consent 
to participate in the study. The patient’s relative or another health care worker unrelated to the 
study assisted patients unable to read and/or write. Parents or guardian provided consent on 
behalf of minors (patients between 15 – 17 years). Written consent was provided by signing 
on special consent forms. Patients were interviewed privately; notes were stored in locked 
cabinets; and the subsequently created electronic database was stored in password protected 
computers. 
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Table 1: Summary of materials and methods for studies used in this thesis 
Aim 
(s) 
Study Design & Study 
population(n = sample size) 
Main outcome of interest Main exposure of interest/ 
Laboratory methods/read- out 
Main statistical analysis 
methods 
1/2 Prospective cohort of 
Tuberculosis patients   
(n = 1696) 
All cause mortality HIV 
Anti-retroviral therapy (ART) 
Cox-proportional hazards model  
3 Prospective cohort of 
Tuberculosis patients without 
multi-drug resistance TB  
(n = 861) 
Unfavorable treatment 
outcome (Death, treatment 
failure and loss to follow 
up) 
Isoniazid resistance by MGIT and 
LJ cultures 
Logistic regression 
4 Prospective cohort of 
Tuberculosis patients 
(n = 234) 
 
Death or survival Anti-gamma interferon level 
(pg/ml) to EBV from supernatant 
on whole blood Assay 
Anti-gamma interferon level 
(pg/ml) to CMV from supernatant 
on whole blood Assay 
Mann-Whitney U test 
5 Prospective cohort of 
Tuberculosis patients  
(n = 234) 
Death or survival 
Severe lung injury at 
baseline (high x-ray score 
>80)  
Severe lung damage post 
treatment (score > 50)  
Unstimulated serum cytokines by 
Sandwich ELISA on serum 
IFN-γ, TNF-α, IL-6,IL-21, IL-17 , 
IL-10 
Logistic regression 
General linear model for repeated 
measure analysis 
  29 
4 RESULTS AND DISCUSSION 
4.1 BURDEN OF TUBERCULOSIS MORTALITY  
Paper I: Int J Infect Dis. 2017 Mar; 56:39-44 
A total of 1696 out of 1805 patients with tuberculosis were included in this paper, among 
them 58 (3.4%) deaths occurred within six months of ATT. We excluded 109 patients 
because they had missing information such as HIV, outcome and age. The excluded patients 
were more likely to be males and had history of illicit drugs use; factors linked with increased 
mortality risk among patients on ATT 
163
. Due to this potential bias therefore, we might have 
underestimated mortality. In the worst case scenario, if all 109 excluded patients are 
considered dead, then, mortality would be 9.3%. Thus, it is very likely that the true burden of 
mortality among patients with TB in our study would be between 3.4 – 9.3%.  
The mortality risk was higher among TB/HIV co-infected individuals (41/514; 8.0%) as 
compared with TB mono-infected patients (17/1182; 1.4%), a phenomenon reported among 
patients with HIV especially in advanced disease 
96, 164, 165
. Most probably as a consequence 
of multiple factors; related to immune suppression, 
16
 immune reconstitution or, not mutually 
exclusive, competing drug toxicity 
111, 166
.   
The median time to death in our cohort was 46 days and at the end of intensive phase of ATT 
two thirds of all the deaths had occurred.  This accelerated initial mortality warrants further 
investigation in relation to exaggerated inflammation. The initial phase of ATT is associated 
with exponential killing of M.tb resulting in a surge of M.tb antigens accessible to the 
immune system 
9
. Worsening of clinical features following effective ATT; also known as 
paradoxical TB, has been described among HIV infected and uninfected individuals and 
might be related to exaggerated inflammatory response 
166, 167
. On the other hand, early deaths 
may signify advanced disease owing TB diagnostic challenges 
37
. It could be hypothesized 
that, late presentation is associated with large TB antigen burden or a mere host exaggerated 
inflammatory response but this remains unanswered by this study and calls for further 
studies. 
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4.2 TUBERCULOSIS MORTALITY PATTERN IN RELATION TO ANTI-
RETROVIRAL THERAPY INITIATION 
Paper I: Int J Infect Dis. 2017 Mar; 56:39-44 
It was apparent that TB/HIV co-infected patients (n = 514) had higher mortality risk thus 
warranting a much deeper scrutiny in relation to HIV treatment. As shown on table 2; patients 
who initiated ART 90 days before starting ATT or within first 14 days of ATT had highest 
mortality (10%), whereas lowest mortality was observed among TB/HIV who had initiated 
ART after 14 days of ATT (5.0%) (Table 2).  
Table 2: Crude mortality pattern in relation to HIV infection and anti-retroviral therapy (Nagu, 
IJID 2017) 
 No. of 
deaths  
No. at 
risk  
Crude 
mortality  
rate (%) 
Median days 
to death (IQR)   
TB+/HIV  17 1182 1.44 46 (32, 62) 
TB+/HIV+; ART >90 days prior to ATT  5 49 10.20 79 (33, 96) 
 TB+/HIV+;  ART ≤ 90 days prior to 
ATT or ≤14 days after ATT 
4 39 10.26 56 (27.5, 72) 
TB+/HIV+;  ART  >14 days after ATT  7 141 4.96 52 (45, 89) 
TB+/HIV+;  No ART  25 285 8.77 37 (26, 59) 
Total 58 1696 3.42 46 (30, 72) 
IQR = Inter Quartile Range, TB = Tuberculosis, ATT = Anti Tuberculosis Therapy 
In this cohort, less than half of TB/HIV patients (229/514) were initiated on ART during the 
follow up period. According to Tanzanian guidelines at the time, all HIV co-infected TB 
patients had to be initiated on ART, preferably after the second week of ATT or within the 
first two weeks in case of severe immunodeficiency (CD4+ T lymphocytes < 50 cells/µL) 
36
. 
The low proportion of HIV infected patients on ART is probably a reflection of a cascade of 
events including late HIV diagnosis, patients’ refusing to take ART, poor referral and lack of 
integration of HIV and TB services at the time. Integration of HIV and TB services has lately 
improved ART uptake to 87% but mortality remains at 6% 
1
. Since, TB clinics serve as an 
important entry point to HIV care and treatment, attempts to harness integrated TB and HIV 
services for appropriate and timely interventions would greatly improve treatment outcomes.  
Using multivariate analysis we compared mortality in relation to ART and ATT among 
TB/HIV co-infected patients, while TB patients without HIV co-infection was the reference 
group. Mortality risk was lowest (three fold) when ART was initiated more than 14 days after 
ATT and highest when ART was initiated before or within the first14 of ATT. Persistent high  
mortality among TB/HIV patients despite good HIV virological control is yet to be 
thoroughly understood among patients on ART. Apparently there is heterogeneity in 
regaining overall immune function after ART initiation despite viral suppression which may 
be associated with lack of TB control and/or mortality 
165
.  It suffices to say at this point that, 
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ART and ATT initiation by themselves are insufficient to avert some deaths among TB/HIV 
patients on ART. It is thus of interest to further investigate the functional immune 
reconstitution in relation to clinical recovery and/or possibility to intervene with host directed 
therapies to reduce these unaccounted mortalities.  
Patients with advanced HIV particularly those with TB/HIV need vigilant follow up of 
clinical, virological and immunological parameters; and prompt action should be taken when 
required
165
. TB/HIV patients, who had initiated ART more than three months prior to ATT in 
our cohort, had low median CD4+ T lymphocyte count (263 cells/µL) and median BMI of 
18.8kg/m
2
. These clinical parameters are associated with opportunistic diseases and thus may 
be synonymous with a failing ART regimen.  We did not quantify HIV viremia, neither did 
we study ART resistance nor the functional CD4+ T cell immune recovery in relation patients 
who died. This might be regarded as an area to improve the quality our study in order to add 
further knowledge for even better TB/HIV management. We discuss inflammation in relation 
to mortality in papers III and IV. 
Given the overall high initial mortality, it is plausible to hypothesize that the individuals who 
died before ART was initiated had been sicker and therefore incomparable to those in the 
ART group. This hypothesis may not likely in our cohort as patients had similar median 
CD4+T cell count and the body mass index (BMI) as seen in Table 3 
Table 3: Distribution of median CD4+ T lymphocyte counts and body mass index by anti-
retroviral therapy among TB/HIV co-infected patients (BMI = Body mass index; IQR = interquartile 
range ) ( Nagu, IJID 2017)  
 Median CD4+ 
(IQR) 
Median BMI 
kg/m2   
TB+/HIV+; ART > 90 days prior to ATT  263 (181, 422) 18.8 (17.0 -21.5) 
 TB+/HIV+;  ART ≤ 90 days prior to ATT or  
≤ 14 days after ATT 
168 (79, 221) 17.4 (15.4, 19.6) 
TB+/HIV+;  ART  >14 days after ATT  151 (69, 220) 18.8 (16.9, 21.2) 
TB+/HIV+;  No ART  331 (158, 471) 18.1 (16.5, 20.4) 
IQR = Inter Quartile Range, TB = Tuberculosis, ATT = Anti Tuberculosis Therapy 
There were yet HIV infected patients who developed TB following ART in our cohort 1 
(Table 2). Unmasking TB is a term coined to TB occurring shortly after initiation of ART 
usually in the first three months of ART 
107, 168
. The increased rates of TB soon after ART are 
probably a result of TB missed during clinical evaluation prior to initiation of ART a fact that 
underscores need for intensified TB screening including use of culture and gene Xpert 
MTB/RIF pre-ART
108
. Unfolding TB might explain the occurrence of TB among the patients 
who had initiated ART around 90 days prior to or immediately after ATT (within 14 days) 
(Table 2). 
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The cohort was almost entirely composed of young to middle aged patients, (91% were ≤ 50 
years; and two thirds were males (67%), a finding that is in keeping with many parts of 
developing countries with high burden of tuberculosis 
23
. Two important things to consider 
include i) increased propensity of such patients to infect their family members as well as 
colleagues at work places even before diagnosis, as determined by mycobacterial load in the 
sputum 
9
. and ii) reduced productivity due to prolonged illness related sick leave leading to 
poverty and malnutrition, a vicious circle of tuberculosis. Indeed, poverty and tuberculosis 
are cousins who must be addressed hand in hand to break the circle 
10
. It is through improved 
living conditions that TB was significantly reduced in high income countries. 
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4.3 RESISTANCE TO ISONIAZID AND TUBERCULOSIS TREATMENT 
OUTCOMES  
Paper II: J Antimicrob Chemother. 2017 Mar 1;72 (3):876-881 
This study included 861 TB-culture positive patients who had both TB treatment outcome 
and anti-TB drug susceptibility reported, without dual resistance to isoniazid and rifampicin 
(MDR) as shown in figure 10. 
 
 
 
 
 
 
 
 
 
 
a
MOTT- Mycobacteria Other Than Tuberculosis 
Figure 10: Patient flow chart (Nagu, JAC 2016) 
Isoniazid resistance was present in among 23 (2.7%) patients, in combinations with 
streptomycin 2/23(8.7%) or ethambutol resistance 2/23 (8.7%). Patients with 
rifampicin/isoniazid co-resistance were excluded prior.  During six months of follow up, 25 
(2.9%) patients died, 10 (1.2%) patients failed treatment and 29 (3.4%) patients were lost 
from follow-up at the clinics.   
A total of 18/23 (78.3%) patients with resistance to isoniazid had successful treatment 
outcomes compared to 779/838 (93.0%) patients with preserved isoniazid susceptibility.  
 
No sputa n =137 
Contaminated n =55  
Culture negative n =244  
MOTT 
a
 n = 4 
 
 
Sputum smear positive adult TB 
recruited in the study n =1805 
Mycobacterium tuberculosis 
culture positive n = 1365 
 
Patients with first line anti- 
tuberculosis drug susceptibility 
pattern assessed n = 933 
MDR TB n = 2,  
No outcome = 70  
Patients with treatment outcomes 
n = 861. 
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At multivariate analysis (Table 4) patients with isoniazid resistance isolates were six times 
more likely to have poor treatment outcome (RR 6.0; 95%CI 1.9 – 18.7; P < 0.01). In 
addition, HIV infection with (RR 2.3; 95%CI 1.0 – 5.2; P = 0.05) or without ART (RR 3.1; 
95% CI 1.5 – 6.2; P < 0.01) was associated with increased risk for unfavorable treatment 
outcomes. (Table4) 
Table 4: Factors associated with unfavorable treatment outcomes among tuberculosis 
patients initiating first line treatment in Tanzania (Nagu, JAC 2016) 
  Univariate Multivariate
a
       
 
RR 
95% C.I. 
for RR    P RR 
95% C.I. 
for RR    P 
Lower Upper Lower Upper 
Age (years) 1.0 1.0 1.0 0.83 1.0 1.0 1.0  0.85 
Male sex 1.4 0.8 2.4 0.27 1.6 0.8 3.3  0.16 
Isoniazid resistance  3.7 1.3 10.2 0.01 6.0 1.9 18.7 <0.01 
HIV status 
   
<0.01
 
   
    
<0.01
 
HIV+/ART+ 2.0 1.0 4.1 
 
2.3 1.0 5.2      
HIV+/ART- 2.8 1.5 5.1 
 
3.1 1.5 6.2     
Primary school or 
below 
1.8 0.8 3.6 0.13 1.2 0.6 2.6 0.60 
Smoking Status         
Never smokers    0.10    0.78 
Past smokers  1.8 1.0 3.1 
 
0.9 0.4 2.0 
 
Current smokers 0.6 0.2 2.7  0.6 0.1 2.6  
BMI (kg/m
2
) 0.9 0.9 1.0 0.19 1.0 0.9 1.0 0.32 
ART = Antiretroviral Therapy, BMI = Body Mass Index RR = Relative Risk CI = Confidence Interval) 
Initial primary isoniazid resistance although has relatively low prevalence, is associated with 
poor outcome. These patients harboring resistant M.tb would otherwise go unnoticed or 
discovered late during treatment since anti-TB drug susceptibility testing is reserved to those 
failing first regimen or patients with a relapsed TB in Tanzania. Phenotypic assessment of 
drug resistance is resource and technically demanding. In many setting Gene Xpert MTB/RIF 
has simplified and improved detection of both TB and rifampicin resistance 
109, 110
.  However, 
given the fact that resistance to isoniazid far more common than rifampicin 
143, 159
, it is likely 
that some cases will be missed by Gene Xpert MTB/RIF system. Patients with undetected 
INH resistant isolates are likely progress to MDR and/or transmit the resistant strain to close 
contact, consequently defeating one of the three strong pillars of the END TB strategy 
10, 33
. 
Accordingly, effective mechanisms to identify and appropriate manage patients with INH 
resistant M.tb are warranted. In addition, simple treatment regimens for INH resistant TB 
ought to be standardized to enable primary medical personnel to easily administer as it is with 
management of drug sensitive and MDR TB 
42, 56
. 
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4.4 ANTI-EBV OR ANTI-CMV INTERFERON GAMMA REACTIVITY AND 
TUBERCULOSIS TREATMENT OUTCOMES 
Paper III: Int J Infect Dis. 2017 Mar; 56:136-139 
We recruited 274 patients in this cohort; forty (40) patients were excluded in this report as 
shown in figure 11 below.  
 
 
 
 
 
 
 
 
 
 
 
 
          Figure 11: Patients flow chart 
A total of 21 deaths occurred during the course of follow up while 213 patients were 
successfully treated. As in cohort 1, we noted in this cohort as well, an accelerated initial 
mortality since 72% of the patients died within the first three months of ATT.  
Patients with tuberculosis who died, exhibited significantly lower median IFN-γ responses to 
ESAT-6 (0.043), CMV pp65 (p= 0.035) and EBNA1 (p = 0.006) in the whole blood assay 
at the time of diagnosis (Figure 12). There was no statistically significant difference in IFN-
γ responses against the following antigens: Rv2958c, Rv0447c, PPD, Ag85A, herpes 
simplex virus 1 (HSV-1) glycoprotein and HIV env. (Figure 12) 
The higher IFN-γ responses to ESAT-6 among survivors of TB, is a reflection of good M.tb 
antigen specific T cell response against M.tb. Coupled with similar pattern specific T cell 
responses against tuberculosis (ESAT-6), responses against EBV and CMV antigens may 
signal a correlation with good immune response against TB. Whether it is a general 
reflection of a good immune system or rather that a prior sensitization with EBV and CMV 
antigens prepared the immune system to be more alert for the mycobacterial antigen is yet 
to be ascertained. It has been reported that non-specific sensitization of alveolar 
macrophages was an important factor for their activation to achieve better control of TB 
infection 
169
. Prospective experimental models with CMV or EBV prior to TB infection 
could help decipher this theory. CMV infections has been shown to drive TB immune 
response towards memory and terminally differentiated effector T cells 
170
, cells which play 
an important role in controlling TB. EBV also induces potent Th1 responses in EBV-
positive individuals. Demonstrating CMV/EBV DNA in these patients would be helpful in 
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interpreting these results in consideration of prior or acute infection which would differ in 
their immune activation states 
15, 170
. 
 
 
 
 
Figure 12: IFN-γ responses to viral and mycobacterial antigens in whole blood assay at the 
time of TB diagnosis in relation to survival during treatment with anti tuberculosis therapy 
(Nagu, IJID 2017) 
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4.5 COULD CYTOKINES PROVIDE A RATIONAL BIOMAKER FOR 
MORTALITY AND LUNG DAMAGE RISK STRATIFICATION 
Paper IV: Manuscript 
At the time of TB diagnosis we found in serum from 234 patients with pulmonary 
tuberculosis significantly increased amounts of IL6 (median: 3863 pg/ml) compared to the 
amounts in serum from seven healthy controls (11pg/ml). In addition IFN-γ, TNF-α and IL-
10 levels were also upregulated in patients with TB compared to the healthy controls but 
the difference were not as profound as it were with IL-6. Patients who died had 
significantly lower median serum levels of IL-6 at diagnosis compared to those who 
survived and were cured. 
The median CXR score at TB diagnosis was 60. Compared to TB survivors, patients who 
died had lower median CXR score at diagnosis. The CXR scores tended to decrease at the 
end of treatment among TB survivors; and in addition we observed a significant linear 
correlation between diagnosis and end of treatment CXR scores (r = 0.44, P < 0.0001). In 
summary, patients with more lung damage at diagnosis tended to have more residual 
damage at the end of treatment. As much as this seems intuitive, the x ray scores could be 
utilized in stratifying those who have high risk of severe lung damage for an intervention 
that might reduce this eventuality. Adjuvant treatment with cytokines and particularly IL6 
(or anti-IL-6, dependent on the timing of treatment), is proposed as one possible clinically 
relevant area for further research as discussed later in this chapter. 
Increasing serum IL-6 and IFN-γ concentrations were significantly associated with reduced 
mortality risk. IL-6 levels observed at diagnosis may protect against death, patients who 
survived TB had significantly increased lung damage at the end of ATT. This observation is 
in line with previous findings in sera of patients with TB from Bangladesh 
171
 and South 
Africa
172
.  
As previously reported, IL-6 is important in clearing large virulent mycobacterial load 
through IFN-γ induction. IL-6-deficient mice were shown to produce significantly lower 
IFN-γ and elevated IL-4 levels in response to M .tb challenge, and succumbed to infection 
within 50 days. Conversely, IL-6-deficient mice infected with the M. bovis BCG vaccine 
strain were able to control the bacterial burden almost as efficiently as wild type mice
173
 
which may probably signify the importance of IL-6 in M.tb but not M.bovis BCG strains. 
At TB diagnosis, high levels of circulating IL-6 associates with extensive lung tissue 
destruction among patients with TB, based on CXR findings. This is in keeping with 
previous findings in patients with pulmonary TB: i) high levels of circulating IL-6 in TB 
patients with or without chronic obstructive pulmonary disease (COPD), in conjunction 
with impaired pulmonary function (marked by reduced FEV1 values) 
174
, and ii) increased 
IL-6 levels in bronchoalveolar lavage fluid, with extensive computed tomography findings 
in the lungs 
175
.  
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Additionally, the IL-6 levels in serum/plasma at the end of the treatment are not much 
lower than after two months of ATT. In support of our observations, several clinical studies 
have shown that IL-6 is upregulated in patients with TB undergoing therapy
176-178
. Thus, it 
appears that the continuation phase of ATT (last four months, daily INH and RIF only), 
while contributing to microbiological cure, does not promote pulmonary tissue healing in 
patients with TB who sustained extensive lung pathology, nor does it help reduce the high 
IL-6 levels present before and during ATT.  
 
Inflammation-induced tissue damage during ATT leads to a decline in life quality in the 
long term, although the patient effectively clears M.tb infection of the lungs 
2, 179
. The link 
between pulmonary TB and impaired lung function despite completion of therapy has also 
been reported for patients in South Africa with drug-sensitive
180
 or multidrug-resistant 
TB
181
. As a consequence, these individuals are denied of a normal lifestyle thereafter, 
which affects their contribution to the workforce and directly affecting the country’s 
socioeconomic development. This scenario calls for host-directed therapy (HDT) targeting 
overt inflammation in addition to conventional antibiotics against M.tb not only to prevent 
early mortality but also to improve life quality of individuals surviving pulmonary TB.    
 
Anti-TNF-α therapy with adalimumab (given adjunctively to standard ATT) during severe 
pulmonary TB has been shown to be life-saving in severe pulmonary TB 
83
. The findings in 
the current study lay the foundation for future studies of HDT targeting exaggerated levels 
of circulating IL-6 in pulmonary TB. Monoclonal antibodies targeting IL-6 (siltuximab) 
and its receptor (tocilizumab) are in the clinic, approved for treating arthritis and 
Castleman’s disease 182. Further clinical trials are underway to test their therapeutic efficacy 
in other indications i.e. diabetes mellitus, pancreatic, lung, ovarian cancers, myeloma
183, 184
. 
One preclinical study in a mouse model of TB showed that blocking IL-6R with a 
monoclonal antibody allows for reduced lung inflammation, improved control of lung M. tb 
burden and prolonged survival of the animals 
185
. However, in the preclinical study, the 
animals were given the anti-IL-6R monoclonal antibody prior to M. tb challenge. Since IL-
6 production by human monocytes is crucial for the early control of M. tb replication 
186
, 
and is required for initiation of adaptive immune responses to M. tb antigens 
187
, we 
propose that HDT directed at reducing circulating levels of IL-6 in patients with pulmonary 
TB would be best administered after the first two months of intensive TB treatment. The 
efficacy of this intervention is best studied in line with reduced inflammatory markers in 
serum i.e. unbound IL-6, C-reactive protein (CRP), tissue scarring (CXR scores) and 
restoration of lung parenchyma and pulmonary function (spirometry). 
 
PTB is mainly local disease whose pathogenesis is complex and resulting from many 
factors including innate and adaptive immunity cells, cytokine and chemokines. Picture we 
deduce from blood therefore, is but a small part of the whole network responsible for TB 
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pathogenesis and control. Yet a very important suggestion that we deduce is that 
intervening with cytokine adjuvant therapy in addition to ATT may modulate this network 
towards better TB control in reducing local inflammation in the lung. 
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5 CONCLUSIONS AND RECOMMENDATIONS 
In Tanzania, mortality among newly diagnosed TB patients during the course of treatment 
with first-line regimen is between 3.4 – 9.3%. This mortality is higher among patients with 
TB/HIV and was lowest when ART was instituted after 14 days of ATT. These findings have 
a great use in real life clinical practice in Tanzania and other similar setting of high rates of 
TB and HIV co-infections. Tuberculosis clinics have shown to be a major entry point for HIV 
care since the majority of our patients were first time diagnosed at TB clinics. In current view 
of “HIV test and treat strategy”, where everyone found to be infected with HIV will be 
treated promptly, it is prudent to wait until the third week of ATT. For patients who have 
been on ART before TB was diagnosed, vigilant monitoring of clinical response and timely 
intervention is essential.  
Background isoniazid resistance is not uncommon and has proved to cause un- favorable 
treatment outcomes in at least 21% of patients with resistance. Current available M.tb culture 
and DST techniques are demanding in terms of infrastructure and skills for country like 
Tanzania. Research for point of care, technology friendly machines for early detection of 
isoniazid and/or rifampicin resistance, need to be prioritized and accessed in routine TB care 
in order to improve treatment outcomes. 
Cytokine responses are essential to successful TB treatment as well as reduction of severe 
lung inflammation. Whereas serum level of IL-6 are comparatively higher than of other 
cytokines in sera of patients with pulmonary tuberculosis and are predictive of survival; they 
could also be a cause of severe pulmonary damage in these patients. Adjunct therapy with IL-
6 may serve as possible target in reducing lung damage following TB disease. Timing is of 
essence: and it may very well be that anti-IL-6 treatment (during the consolidation phase of 
the TB disease, associated with lung damage), could be a clinically viable option; similarly to 
the ‘double-edged sword’ described for anti-TNF alpha blockage during different phases of 
TB disease development 
83
  
More studies on inflammation and lung damage, including linking them to lung function 
tests; longer term cytokine follow for chronic lung inflammation including (COPD); Trials of 
IL 6 for TB patients as adjuvant therapy especially during the continuation phase of ATT are 
really essential. Further gauging anti-CMV/EBV responses in M.tb disease in patients with 
known CMV/EBV viremia would certainly add value.   
 
 
 
  
  41 
6 ACKNOWLEDGEMENTS 
Indeed it has been a long journey, full of adventures and certainly educative in many ways. 
I will always be grateful to be part of Karolinska Institutet as a doctoral student. Many 
people have contributed to making this thesis, I would like to thank you all. 
To my supervisors; 
Professor Markus Maeurer my main supervisor, thank you so much for accepting me as 
your PhD student at TIM. I am sure it wasn’t so easy for you to fit my short stays in 
Sweden with you busy schedule. You accorded me with the necessary tools and support as 
much as possible. Mark, you are a talented scientist with unwavering dedication to 
excellence and you are a gifted teacher. It was a privilege to be your student and hopefully 
you shall continue to mentor me remotely. 
Professor Ferdinand Mugusi, you are an incredible supervisor, passionate clinician and 
brilliant researcher. You played the double role of a supervisor and a mentor; I am grateful 
for your untiring support and numerous opportunities to learn.  You allowed me to venture 
into the unknown to test hypotheses; and never ceased to guide. It was an honored to be 
your PhD student, and even more exciting that I will continue to shadow you in respiratory 
and infectious disease clinical practice. 
Professor Matee, you have known me a long way in research training. You were my 
supervisor for master’s thesis as well as this Ph.D. training.  Thank you for you all the 
support in setting up the laboratory and immense help in reviewing my manuscripts.  
Dr Rebecca Axelsson, I am grateful for all the help with the immunology experiments. 
Distance between Tanzania and Sweden was reduced to minimum because you were just a 
skype call away to make things work out. Thanks Rebecca for taking part of your maternity 
leave to help with paper work and in reading cover story of this thesis. 
I would also like to thank former supervisors Dr Isabelle Magalhaes and Antony Rothfuchs 
for accepting to be co-supervisors and checking on me. Isabelle, thank you for assisting 
with the project start-up; and for the admission seminar rehearsal.  
To my Mentors; 
Professor Muhammad Bakari, you have been a key person to my career development and 
PhD training. You associated me with SIDA project and never hesitated to intervene when 
things did not seem to work. Thank you for the initial research skills as my master’s thesis 
main supervisor, without which the beginning of my Ph.D. would have been harder.  
Professor Wafaie Fawzi, thank you for being my mentor for the Global Health Scholar 
program which provided major part of the funds to carry out research for the first two 
papers in this thesis. I appreciate your support and encouragement as well as the many 
learning opportunities I obtained through you.  
 42 
Sir Alimuddin Zumla, it has been a great privilege to know, meet and work with you. 
Thank you for generously sharing your vast knowledge and experience in tuberculosis with 
me. I appreciate your help with manuscript revisions, your advices and support. 
Professor Pallangyo, you read my manuscripts and provided so many valuable inputs. 
Thank you for all the advice, encouragement and support during this training.  
Dr Johnson Lwakatare, being the next door office neighbor to my home supervisor, it was 
convenient for me but I am sure not for you. You accommodated my unscheduled visits and 
offered advice. Thank you. 
Professor Julie Makani, you are amazing in so many ways; brilliant researcher, dedicated 
clinician and great teacher. You have been very inspirational and helpful in my training, 
thanks Julie. 
Dr Martin Rao, you are a great person, thank you for who you are and for all the help you 
provided me with. Your knowledge in TB as well as scientific writing skills are remarkable; 
and have been very useful during my training.  You were a key contact here in Stockholm 
while I was in Dar es Salaam and a very good link with Mark. Thanks for helping with 
receiving and storage of my samples. Thank you for the help in manuscripts and on the 
thesis as well.  
To SIDA, I would like to sincerely thank the government of Sweden through SIDA who 
funded my training. It was a great opportunity to learn and network.  
Special thanks to Professor Gunnel Biberfeld and Professor Anna Mia Ekström HIV-
subprogram coordinators for all practical help. Anna Mia, in addition to being SIDA 
coordinator, you offered advice whenever I called on you. Professor Said Aboud, you were 
not only SIDA coordinator in Tanzania but also a great help in laboratory work. 
To Muhimbili University of Health and Allied Sciences (MUHAS); many thanks for 
your support as an employer. I appreciate your initiative to pursue SIDA training grant. I 
hope attained knowledge and skills will benefit the university and Tanzanians. 
To the patients, you have contributed in the search of knowledge for a good cause. Your 
sacrifice is honored and I remain indebted to you and all patients.  To the patients who died 
during the study, may you Rest in Peace.  
To the department of Laboratory medicine; Special thanks to Professor Matti Sällberg, 
Professor Antony Wright, Professor Moustapha Hassan, Dr Jenny Degerholm 
Langsmo, and Arja Kramsu for your great support throughout training but more 
specifically, during the final months of my training. I am grateful for all you did to make 
my defense go through as planned. I am proud to be a trainee in this department.  
To the department of Internal Medicine MUHAS; many thanks to the former and 
current heads of department, Professor Janet Lutale and Dr Paschal Ruggajo and all 
  43 
colleagues for your advice and well wishes. Special thanks to Dr Grace Shayo, Dr Ewaldo 
Komba, Professor Eden Maro for taking my responsibilities whenever I travelled. 
To TIM members – F73-79 corridor – thank you for the happy moments, I enjoyed the 
fikkas. Special thanks to Associate Professor Helen Kaipe, you efficiently respond to 
matters with great speed and highest level of precision. Thank you for trouble shooting with 
my defense application process. Gunbritt Lindholm, thank you for fixing access cards and 
all practical help in the hospital. 
To Professor Markus Maeurer’s research group members former and current; Lalit 
Rane, Aditya Lambati, Nancy Alvarez-Corrales, Giovanni Ferrara, Thomas Poiret, Luo 
(a.k.a. Petter), Liu Zhenjiang, Qingda Meng, Annurupa Nagchowdhury, Esther Schoutrop, 
Geogia Paraschoudi and Chaniya Leepiyasakulchai – I am grateful to you all. You were 
wonderful in many ways; from practical issues when I stayed in Stockholm to great 
scientific discussions. I learnt a lot from our interactions. Thomas, thank you for bearing 
with my clumsiness in the lab at the beginning; thanks too for helping to secure storage for 
my samples. Marlene and Moa, I am grateful for all your support with administrative 
issues. 
Co-authors; Dr Lulu Fundikira and Dr Zuhura Nkumbih, I appreciate your help in 
interpretation scoring chest radiographs. Ramadhani Mwiru –thank you for great help with 
stastical analysis. 
National Tuberculosis and Leprosy Program (NTLP). I would like to appreciate the 
generous support from the program through the former (Dr Said Egwaga) and current (Dr 
Beatrice Mutayoba) program managers, which enabled smooth navigation through TB 
clinics. Dr Egwaga thank you for the Tuberculin PPD reagents.  
Research staff: I would like to thank all staff who assisted with the research; all the 
clinicians and nurses at the study sites; Sr Magreth Matekele and Sr Happiness for 
coordinating the clinical studies; laboratory technicians: Colman Mchau, Salome Kihampa 
and Betty Mchaki, Zacharia Mtulo, Edward Shogolo, Bryceson Malleo Daphne Mtunga and 
Basra Doulla. Special thanks to Gladness Kiwelu and Thekla Mtomoni for assisting with 
data entry; and to Halfan, for transportation of samples. 
SIDA PhD colleagues; Dr Matilda Ngarina, Dr Patricia Munseri, Dr Edith Tarimo, Dr 
Abel Makubi, Dr Agricola Joachim, Dr Frank Msafiri, Dr Majigo Mtebe, Dr Theodora 
Daniel, Roselyne Urio, Masunga Iseselo, Dr Goodluck Lyatuu and Dr Fadhluni Alwy; 
thank you all for your help.  Dr Helga Naburi and Dr Dawa Mushi you were a great friends 
and good company in Sweden.  
Friends in Sweden Associate Professor Anna-Berit Arvidson, thank you for comments on 
my “kappa”, Rashmi, Lien, Dr Shweta, Dr Muslima (Say hi to Ajazi) and Dr Uzmal I will 
treasure the memories. 
 44 
To my Christian community of our Lady of perpetual help – Dar es Salaam, my neighbors; 
Martha Kamuhabwa and Domitila Makubi thank you for all you have been. 
To my friends and family; thank you for your well wishes, encouragement, support and 
love all of which sustained me throughout the training period. Mamdogo Yacinta, you are a 
unique person to me; friend, sister and auntie. Thank you for all you did all these seven 
years, so my stay away from home was not so stressful. Ephrasia, you had to sacrifice a lot 
to stay home with Jo-Marie and Davidson. Thank you Efuu, it meant a lot. My cousins 
Esther, Basila, Anna, Patricia and Jullie; thank you for your support. Redimna and Lucy, 
you made sure kids were as comfortable as possible. Leticia, I left you home almost all the 
time, your help and leadership are greatly appreciated. Betty thanks for the encouraging 
conversations over the phone. 
To my in laws, you are an adorable family. Emma and Nelson; Janet and Immanuel, Laura 
and Richard; and Victor, thank you for your understanding and support in many ways. All 
of you were a phone call away; dada Emma thank you for sending references whenever I 
called on you. Janet and Laura thank you for making it to school occasions. My mother in-
law, aka “fogo” thank you for your encouragement, support and reassuring words which 
ended unnecessary worries.  
To my parents Mary and Joseph Nagu, I will always be grateful to your ever loving 
parenting. Mama, you believed in me and gave courage and to go on. Thanks for spoiling 
wajukuu, every bit is appreciated mama and I love you so much. Daddy, you encouraged 
and supported me all along. It’s a pity you missed it by a few months, all I have is to 
imagine your smile as it comes to the end. My siblings Neema and Deogratius, we not only 
share parents but also very special bond. Thank you for being wonderful persons I could 
count on. Fr. Wolfgang Pissa O.F.M.Cap; a brother and spiritual advisor, thank you for 
helping to me to conquer my fears and remain calm. 
To my family; Jo-Marie, Davidson and Lawrence, it couldn’t be easier without you. 
Sweetheart Jojolito when I started this journey you were only 13 months, you endured 
lengths of times without mommy but became a responsible and courageous girl. Thank you 
my daughter for hanging in there. 
Davidson, mommy’s boy – Ooh what an encouraging personality? Thank you for all your 
love and prayers. I still recall the warmth of your hug as you said God will take care of you 
mama, when I took my first flight to Sweden, thank you Davidson. 
Lawrence my husband, you are the one who shouldered everything at the expense of your 
own professional development – struggling with loneliness, taking care of our children and 
my frustrations; you saw it all. I had peace to carry out my training knowing you were 
there. I have no better definition of a gentleman than I find in you. Thank you so much. 
To God be the glory, great things he hath done for me throughout this training, may the 
service I shall provide be accepted as a sign of my gratitude to the Most High.
  45 
7 REFERENCES 
1. National Tuberculosism and Leprosy Program. National Tuberculosis and leprosy 
Program Annual report for 2014. Dar es Salaam; 2015. 
2. Manji M, Shayo G, Mamuya S, Mpembeni R, Jusabani A, Mugusi F. Lung functions 
among patients with pulmonary tuberculosis in Dar es Salaam - a cross-sectional study. 
BMC pulmonary medicine. 2016; 16(1): 58. 
3. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, et al. Early 
mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income 
countries (LMIC): a systematic review and meta-analysis. PloS one. 2011; 6(12): 
e28691. 
4. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving 
HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005; 
19(18): 2109-16. 
5. Philip R. An Address on Koch's discovery of the Tubercle Bacillus: Some of its 
implications and results. British medical journal. 1932; 2(3730): 1-5. 
6. Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. The American 
review of respiratory disease. 1967; 95(3): 435-42. 
7. Loudon RG, Roberts RM. Singing and the dissemination of tuberculosis. The American 
review of respiratory disease. 1968; 98(2): 297-300. 
8. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary 
tuberculosis. The American review of respiratory disease. 1969; 99(1): 109-11. 
9. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: The effects of 
chemotherapy. Tubercle. 1976; 57(4): 275-99. 
10. Raviglione M, Sulis G. Tuberculosis 2015: Burden, Challenges and Strategy for 
Control and Elimination. Infectious disease reports. 2016; 8(2): 6570. 
11. Milburn HJ. Primary tuberculosis. Current opinion in pulmonary medicine. 2001; 7(3): 
133-41. 
12. Dorhoi A, Reece ST, Kaufmann SH. Immunity to intracellular bacteria. Philadelphia: 
Wolters Kluwer Health, Lippincott Williams & Wilkins; 2012. 
13. Dannenberg Jr AM. Macrophage turnover, division and activation within developing, 
peak and “healed” tuberculous lesions produced in rabbits by BCG. Tuberculosis. 
2003; 83(4): 251-60. 
14. Cooper AM, Mayer-Barber KD, Sher A. Role of innate cytokines in mycobacterial 
infection. Mucosal immunology. 2011; 4(3): 252-60. 
15. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, et al. T-cell 
activation is an immune correlate of risk in BCG vaccinated infants. Nature 
communications. 2016; 7: 11290. 
16. Jambo KC, Banda DH, Afran L, Kankwatira AM, Malamba RD, Allain TJ, et al. 
Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung 
CD4(+) T-cell responses to mycobacteria. American journal of respiratory and critical 
care medicine. 2014; 190(8): 938-47. 
 46 
17. Mariani F, Goletti D, Ciaramella A, Martino A, Colizzi V, Fraziano M. Macrophage 
response to Mycobacterium tuberculosis during HIV infection: relationships between 
macrophage activation and apoptosis. Current molecular medicine. 2001; 1(2): 209-16. 
18. Guirado E, Schlesinger LS. Modeling the Mycobacterium tuberculosis Granuloma – 
the Critical Battlefield in Host Immunity and Disease. Frontiers in Immunology. 2013; 
4: 98. 
19. Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculous 
granuloma: an unsuccessful host defence mechanism providing a safety shelter for the 
bacteria? Clin Dev Immunol. 2012; 2012: 139127. 
20. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, et al. Early events in 
Mycobacterium tuberculosis infection in cynomolgus macaques. Infection and 
immunity. 2006; 74(7): 3790-803. 
21. von Reyn CF, Kimambo S, Mtei L, Arbeit RD, Maro I, Bakari M, et al. Disseminated 
tuberculosis in human immunodeficiency virus infection: ineffective immunity, 
polyclonal disease and high mortality. The international journal of tuberculosis and 
lung disease : the official journal of the International Union against Tuberculosis and 
Lung Disease. 2011; 15(8): 1087-92. 
22. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-
estimation Using Mathematical Modelling. PLoS Medicine. 2016; 13(10): e1002152. 
23. World Health Organization. Global Tuberculosis Report 2016. Geneva; 2016. 
24. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, 
regional, and national incidence, prevalence, and years lived with disability for 328 
diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global 
Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1211-59. 
25. Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, et al. Persistent latent 
tuberculosis reactivation risk in United States immigrants. American journal of 
respiratory and critical care medicine. 2014; 189(1): 88-95. 
26. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Current 
opinion in HIV and AIDS. 2009; 4(4): 325-33. 
27. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a 
systematic review of 13 observational studies. PLoS Med. 2008; 5(7): e152. 
28. Dodd PJ, Looker C, Plumb ID, Bond V, Schaap A, Shanaube K, et al. Age- and Sex-
Specific Social Contact Patterns and Incidence of Mycobacterium tuberculosis 
Infection. Am J Epidemiol. 2016; 183(2): 156-66. 
29. Senkoro M, Kumar AM, Chinnakali P, Mfinanga SG, Egwaga S, Kamara V, et al. 
Population impact of factors associated with prevalent pulmonary tuberculosis in 
Tanzania. The international journal of tuberculosis and lung disease : the official 
journal of the International Union against Tuberculosis and Lung Disease. 2016; 
20(10): 1326-33. 
30. GBD-2016-Causes-of-Death-Collaborators. Global, regional, and national age-sex 
specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the 
Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1151-210. 
31. World Health Organisation. Definitions and reporting framework for tuberculosis - 
2013 revision (updated December 2014). Geneva: WHO; 2014. 
  47 
32. World Health Organisation. Antimicrobial resistance: Global report on surveillance. 
WHO; 2014. 
33. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new 
End TB Strategy. The Lancet. 2015; 385(9979): 1799-801. 
34. Bomanji JB, Gupta N, Gulati P, Das CJ. Imaging in tuberculosis. Cold Spring Harb 
Perspect Med. 2015; 5(6). 
35. Shayo GA, Minja LT, Egwaga S, Bakari M, Mugusi FM. Symptom-based screening 
tool in ruling out active tuberculosis among HIV-infected patients eligible for isoniazid 
preventive therapy in Tanzania. Tropical medicine & international health : TM & IH. 
2014; 19(6): 726-33. 
36. National Tuberculosis and Leprosy Programme. Manual for the Management of 
Tuberculosis and Leprosy. 6th ed. Dar es Salaam: United-Republic-of-Tanzania; 2013. 
37. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, et al. High rates of 
clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in 
Tanzania. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America. 2005; 40(10): 1500-7. 
38. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. 
Official American Thoracic Society/Infectious Diseases Society of America/Centers for 
Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis 
in Adults and Children. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2017; 64(2): e1-e33. 
39. Global-Laboratory-Initiative. Mycobacteriology laboratory manual. Geneva: WHO 
Stop TB Partnership. 2014. 
40. World Health Organisation. WHO Guidelines Approved by the Guidelines Review 
Committee.  Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- 
and Middle- Income Countries: Policy Statement. Geneva: World Health Organization; 
2011. 
41. World Health Organisation. WHO Guidelines Approved by the Guidelines Review 
Committee.  Recommendation on 36 Months Isoniazid Preventive Therapy to Adults 
and Adolescents Living with HIV in Resource-Constrained and High TB- and HIV-
Prevalence Settings: 2015 Update. Geneva: WHO; 2015. 
42. World Health Organisation. WHO treatment guidelines for drug-resistant tuberculosis 
2016 update. Geneva: WHO; 2016. 
43. Pathmanathan I, Date A, Coggin WL, Nkengasong J, Piatek AS, Alexander H. Rolling 
Out Xpert(R) MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity 
for Systems Strengthening. Afr J Lab Med. 2017; 6(2). 
44. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-γ release assays for the 
rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden 
settings. Current opinion in pulmonary medicine. 2009; 15(3): 188-200. 
45. Banaei N, Gaur RL, Pai M. Interferon Gamma Release Assays for Latent Tuberculosis: 
What Are the Sources of Variability? Journal of clinical microbiology. 2016; 54(4): 
845-50. 
 48 
46. Clifford V, He Y, Zufferey C, Connell T, Curtis N. Interferon gamma release assays for 
monitoring the response to treatment for tuberculosis: A systematic review. 
Tuberculosis (Edinburgh, Scotland). 2015; 95(6): 639-50. 
47. Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, et al. A 
simple, valid, numerical score for grading chest x-ray severity in adult smear-positive 
pulmonary tuberculosis. Thorax. 2010; 65(10): 863-9. 
48. Nachiappan AC, Rahbar K, Shi X, Guy ES, Mortani Barbosa EJ, Jr., Shroff GS, et al. 
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. 
Radiographics. 2017; 37(1): 52-72. 
49. Omri HE, Hascsi Z, Taha R, Szabados L, Sabah HE, Gamiel A, et al. Tubercular 
Meningitis and Lymphadenitis Mimicking a Relapse of Burkitt's Lymphoma on (18)F-
FDG-PET/CT: A Case Report. Case reports in oncology. 2015; 8(2): 226-32. 
50. Wang SY, Luo DL, Chen G, Wang SX. 18F-FDG PET/CT Images in a Patient With 
Primary Chest Wall Tuberculosis Mimicking Malignant Tumor. Clinical nuclear 
medicine. 2016; 41(4): 323-5. 
51. Wang SB, Ji YH, Wu HB, Wang QS, Zhou WL, Lv L, et al. PET/CT for differentiating 
between tuberculous peritonitis and peritoneal carcinomatosis: The parietal peritoneum. 
Medicine. 2017; 96(2): e5867. 
52. Ankrah AO, van der Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans 
AW. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Transl Imaging. 
2016; 4: 131-44. 
53. Lefebvre N, Argemi X, Meyer N, Mootien J, Douiri N, Sferrazza-Mandala S, et al. 
Clinical usefulness of 18F-FDG PET/CT for initial staging and assessment of treatment 
efficacy in patients with lymph node tuberculosis. Nucl Med Biol. 2017; 50: 17-24. 
54. Ye M, Huang J, Wang J, Ren J, Tu J, You W, et al. Multifocal musculoskeletal 
tuberculosis mimicking multiple bone metastases: a case report. BMC infectious 
diseases. 2016; 16: 34. 
55. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al. 
Persisting positron emission tomography lesion activity and Mycobacterium 
tuberculosis mRNA after tuberculosis cure. Nature medicine. 2016; 22(10): 1094-100. 
56. World Health Organisation. Treatment of Tuberculosis Guidelines. 4th ed. Geneva: 
WHO; 2010. 
57. Gualano G, Capone S, Matteelli A, Palmieri F. New Antituberculosis Drugs: From 
Clinical Trial to Programmatic Use. Infectious disease reports. 2016; 8(2): 6569. 
58. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis 
treatment and management--an update on treatment regimens, trials, new drugs, and 
adjunct therapies. The Lancet Respiratory medicine. 2015; 3(3): 220-34. 
59. Weiss P, Chen W, Cook VJ, Johnston JC. Treatment outcomes from community-based 
drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. 
BMC infectious diseases. 2014; 14: 333. 
60. Guglielmetti L, Le Du D, Jachym M, Henry B, Martin D, Caumes E, et al. 
Compassionate use of bedaquiline for the treatment of multidrug-resistant and 
extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clinical 
  49 
infectious diseases : an official publication of the Infectious Diseases Society of 
America. 2015; 60(2): 188-94. 
61. Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant 
tuberculosis. Infection and drug resistance. 2015; 8: 359-66. 
62. Kaufmann SH, Flesch IE. The role of T cell--macrophage interactions in tuberculosis. 
Springer Semin Immunopathol. 1988; 10(4): 337-58. 
63. Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. 
Ann Rheum Dis. 2002; 61 Suppl 2: ii54-8. 
64. Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, et al. 
Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and 
anti-inflammatory cytokines is associated with sterilization. PLoS pathogens. 2015; 
11(1): e1004603. 
65. Dorhoi A, Kaufmann SH. Tumor necrosis factor alpha in mycobacterial infection. 
Seminars in immunology. 2014; 26(3): 203-9. 
66. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, Pearl JE, et al. 
Interleukin 12p40 is required for dendritic cell migration and T cell priming after 
Mycobacterium tuberculosis infection. The Journal of experimental medicine. 2006; 
203(7): 1805-15. 
67. Drennan MB, Nicolle D, Quesniaux VJ, Jacobs M, Allie N, Mpagi J, et al. Toll-like 
receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection. The 
American journal of pathology. 2004; 164(1): 49-57. 
68. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 
responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium 
tuberculosis. The Journal of experimental medicine. 2005; 202(12): 1715-24. 
69. Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR, Jr., Ernst JD. Potent inhibition of 
macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is 
independent of mature mycobacterial lipoproteins but dependent on TLR2. Journal of 
immunology (Baltimore, Md : 1950). 2006; 176(5): 3019-27. 
70. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT, et al. Toll-like 
receptor 2-dependent inhibition of macrophage class II MHC expression and antigen 
processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. Journal of 
immunology (Baltimore, Md : 1950). 2001; 167(2): 910-8. 
71. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, Fountain JJ, et al. 
ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis 
infection are initiated in the mediastinal lymph nodes. Proceedings of the National 
Academy of Sciences of the United States of America. 2008; 105(31): 10961-6. 
72. Mourik BC, Lubberts E, de Steenwinkel JEM, Ottenhoff THM, Leenen PJM. 
Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: 
Lessons Learned from Autoimmune Diseases. Front Immunol. 2017; 8: 294. 
73. Su WL, Perng WC, Huang CH, Yang CY, Wu CP, Chen JH. Association of reduced 
tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but 
increased IL-10 expression with improved chest radiography in patients with 
pulmonary tuberculosis. Clinical and vaccine immunology : CVI. 2010; 17(2): 223-31. 
 50 
74. Green AM, Difazio R, Flynn JL. IFN-gamma from CD4 T cells is essential for host 
survival and enhances CD8 T cell function during Mycobacterium tuberculosis 
infection. Journal of immunology (Baltimore, Md : 1950). 2013; 190(1): 270-7. 
75. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role 
for interferon gamma in resistance to Mycobacterium tuberculosis infection. The 
Journal of experimental medicine. 1993; 178(6): 2249-54. 
76. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, et al. Innate 
and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct 
pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity. 
2011; 35(6): 1023-34. 
77. Awoniyi DO, Teuchert A, Sutherland JS, Mayanja-Kizza H, Howe R, Mihret A, et al. 
Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for 
TB disease. The Journal of infection. 2016; 73(3): 219-30. 
78. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992; 
10: 411-52. 
79. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune 
response in tuberculosis. Annu Rev Immunol. 2013; 31: 475-527. 
80. Chowdhury IH, Ahmed AM, Choudhuri S, Sen A, Hazra A, Pal NK, et al. Alteration of 
serum inflammatory cytokines in active pulmonary tuberculosis following anti-
tuberculosis drug therapy. Molecular immunology. 2014; 62(1): 159-68. 
81. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, Ryffel B. Fatal 
Mycobacterium tuberculosis infection despite adaptive immune response in the absence 
of MyD88. The Journal of clinical investigation. 2004; 114(12): 1790-9. 
82. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis 
risks. The Lancet Infectious diseases. 2008; 8(10): 601-11. 
83. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening 
tuberculosis. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. 2009; 48(10): 1429-32. 
84. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, et al. IL-1 Receptor-
Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to 
Mycobacterium tuberculosis Infection. The Journal of Immunology. 2007; 179(2): 
1178-89. 
85. Juffermans NP, Florquin S, Camoglio L, Verbon A, Kolk AH, Speelman P, et al. 
Interleukin-1 signaling is essential for host defense during murine pulmonary 
tuberculosis. The Journal of infectious diseases. 2000; 182(3): 902-8. 
86. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. 
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon 
crosstalk. Nature. 2014; 511(7507): 99-103. 
87. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 
and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after 
vaccination and during Mycobacterium tuberculosis challenge. Nature immunology. 
2007; 8(4): 369-77. 
  51 
88. Wareham AS, Tree JA, Marsh PD, Butcher PD, Dennis M, Sharpe SA. Evidence for a 
role for interleukin-17, Th17 cells and iron homeostasis in protective immunity against 
tuberculosis in cynomolgus macaques. PloS one. 2014; 9(2): e88149. 
89. Whittaker E, Nicol M, Zar HJ, Kampmann B. Regulatory T Cells and Pro-
inflammatory Responses Predominate in Children with Tuberculosis. Front Immunol. 
2017; 8: 448. 
90. Redford PS, Murray PJ, O'Garra A. The role of IL-10 in immune regulation during M. 
tuberculosis infection. Mucosal immunology. 2011; 4(3): 261-70. 
91. Hussain R, Talat N, Shahid F, Dawood G. Longitudinal tracking of cytokines after 
acute exposure to tuberculosis: association of distinct cytokine patterns with protection 
and disease development. Clinical and vaccine immunology : CVI. 2007; 14(12): 1578-
86. 
92. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. 
Cold Spring Harbor perspectives in biology. 2014; 6(10): a016295. 
93. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis research & 
therapy. 2006; 8 Suppl 2: S2. 
94. Nagabhushanam V, Solache A, Ting LM, Escaron CJ, Zhang JY, Ernst JD. Innate 
inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits 
macrophage responses to IFN-gamma. Journal of immunology (Baltimore, Md : 1950). 
2003; 171(9): 4750-7. 
95. Zumla A, Rao M, Dodoo E, Maeurer M. Potential of immunomodulatory agents as 
adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC medicine. 
2016; 14: 89. 
96. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths 
from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. Aids. 
2012; 26(17): 2121-33. 
97. Cox JA, Lukande RL, Nelson AM, Mayanja-Kizza H, Colebunders R, Van Marck E, et 
al. An autopsy study describing causes of death and comparing clinico-pathological 
findings among hospitalized patients in Kampala, Uganda. PloS one. 2012; 7(3): 
e33685. 
98. Bates M, Mudenda V, Shibemba A, Kaluwaji J, Tembo J, Kabwe M, et al. Burden of 
tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan 
Africa: a prospective descriptive autopsy study. The Lancet Infectious diseases. 2015; 
15(5): 544-51. 
99. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, Nyirenda ST, et al. 
Pathology and causes of death in a group of 128 predominantly HIV-positive patients 
in Botswana, 1997-1998. The international journal of tuberculosis and lung disease : 
the official journal of the International Union against Tuberculosis and Lung Disease. 
2002; 6(1): 55-63. 
100. Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, et al. 
Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, 
Kenya. Journal of acquired immune deficiency syndromes. 2000; 24(1): 23-9. 
101. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, et al. Whole-
genome sequencing to establish relapse or re-infection with Mycobacterium 
 52 
tuberculosis: a retrospective observational study. The Lancet Respiratory medicine. 
2013; 1(10): 786-92. 
102. Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA. Apoptosis as a 
mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. The 
Journal of clinical investigation. 1991; 87(5): 1710-5. 
103. Chetty S, Govender P, Zupkosky J, Pillay M, Ghebremichael M, Moosa MY, et al. Co-
infection with Mycobacterium tuberculosis impairs HIV-Specific CD8+ and CD4+ T 
cell functionality. PloS one. 2015; 10(3): e0118654. 
104. Sada-Ovalle I, Ocana-Guzman R, Perez-Patrigeon S, Chavez-Galan L, Sierra-Madero 
J, Torre-Bouscoulet L, et al. Tim-3 blocking rescue macrophage and T cell function 
against Mycobacterium tuberculosis infection in HIV+ patients. Journal of the 
International AIDS Society. 2015; 18: 20078. 
105. Espert L, Beaumelle B, Vergne I. Autophagy in Mycobacterium tuberculosis and HIV 
infections. Frontiers in cellular and infection microbiology. 2015; 5: 49. 
106. Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, et al. Timing 
of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for 
Testing and Treatment. Journal of acquired immune deficiency syndromes. 2016; 
72(5): 572-8. 
107. Naidoo K, Karim QA, Bhushan A, Yende-Zuma N, McHunu PK, Frohlich J, et al. 
High rates of tuberculosis in patients accessing HAART in rural South Africa. Journal 
of acquired immune deficiency syndromes. 2014; 65(4): 438-46. 
108. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensive 
tuberculosis screening for HIV-infected patients starting antiretroviral therapy in 
Durban, South Africa. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2010; 51(7): 823-9. 
109. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of 
Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV 
prevalence in South Africa: a pragmatic randomised trial. PLoS Med. 2014; 11(11): 
e1001760. 
110. Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, et al. 
Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary 
Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher 
Prevalence Settings. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2016; 62(9): 1081-8. 
111. Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, et al. Liver enzyme 
abnormalities and associated risk factors in HIV patients on efavirenz-based HAART 
with or without tuberculosis co-infection in Tanzania. PloS one. 2012; 7(7): e40180. 
112. Manosuthi W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and 
tuberculosis. AIDS research and therapy. 2016; 13: 22. 
113. Belard S, Remppis J, Bootsma S, Janssen S, Kombila DU, Beyeme JO, et al. 
Tuberculosis Treatment Outcome and Drug Resistance in Lambarene, Gabon: A 
Prospective Cohort Study. The American journal of tropical medicine and hygiene. 
2016; 95(2): 472-80. 
  53 
114. Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V, et al. Nevirapine 
or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological 
failure relationship. The Journal of antimicrobial chemotherapy. 2015; 70(1): 225-32. 
115. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. 
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug 
targeting the human immunodeficiency virus 1 integrase enzyme. Drug metabolism and 
disposition: the biological fate of chemicals. 2007; 35(9): 1657-63. 
116. Sunpath H, Winternheimer P, Cohen S, Tennant I, Chelin N, Gandhi RT, et al. Double-
dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis 
treatment in South Africa. The international journal of tuberculosis and lung disease : 
the official journal of the International Union against Tuberculosis and Lung Disease. 
2014; 18(6): 689-93. 
117. Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase 
inhibitor. The Journal of antimicrobial chemotherapy. 2013; 68(2): 250-6. 
118. Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, et al. Long-
Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the 
Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian 
Patients. Journal of clinical pharmacology. 2016. 
119. Mariana N, Purwantyastuti, Instiaty, Rusli A. Efavirenz Plasma Concentrations and 
HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin. 
Acta medica Indonesiana. 2016; 48(1): 10-6. 
120. Mukonzo JK, Bisaso RK, Ogwal-Okeng J, Gustafsson LL, Owen JS, Aklillu E. 
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based 
antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics. 
2016; 17(6): 603-13. 
121. Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, et al. Randomized 
pharmacokinetic evaluation of different rifabutin doses in African HIV- infected 
tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC 
pharmacology & toxicology. 2014; 15: 61. 
122. Mallikaarjun S, Wells C, Petersen C, Paccaly A, Shoaf SE, Patil S, et al. Delamanid 
Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No 
Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrobial agents 
and chemotherapy. 2016; 60(10): 5976-85. 
123. Reniers G, Blom S, Calvert C, Martin-Onraet A, Herbst AJ, Eaton JW, et al. Trends in 
the burden of HIV mortality after roll-out of antiretroviral therapy in KwaZulu-Natal, 
South Africa: an observational community cohort study. Lancet HIV. 2017; 4(3): e113-
e21. 
124. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al. 
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. The 
Journal of antimicrobial chemotherapy. 2000; 45(6): 859-70. 
125. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of 
drugs in patients with pulmonary tuberculosis. The American review of respiratory 
disease. 1980; 121(6): 939-49. 
126. Mehta JB, Dutt AK, Harvill L, Henry W. Isoniazid preventive therapy for tuberculosis. 
Are we losing our enthusiasm? Chest. 1988; 94(1): 138-41. 
 54 
127. Companion Handbook to the WHO Guidelines for the Programmatic Management of 
Drug-Resistant Tuberculosis. Geneva: World Health Organization 2014.; 2014. 
128. Harries AD, Lawn SD, Suthar AB, Granich R. Benefits of combined preventive therapy 
with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-
dose, single tablet coformulation. The Lancet Infectious diseases. 2015; 15(12): 1492-6. 
129. Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid 
preventive therapy may outweigh resistance risks in a declining TB/HIV co-epidemic. 
Aids. 2016. 
130. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A Trial of Early 
Antiretrovirals and Isoniazid Preventive Therapy in Africa. The New England journal 
of medicine. 2015; 373(9): 808-22. 
131. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month 
versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV 
infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 
2011; 377(9777): 1588-98. 
132. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of 
isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis 
coinfected populations. Proceedings of the National Academy of Sciences of the United 
States of America. 2006; 103(18): 7042-7. 
133. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. 
Effect of improved tuberculosis screening and isoniazid preventive therapy on 
incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, 
Brazil: a stepped wedge, cluster-randomised trial. The Lancet Infectious diseases. 2013; 
13(10): 852-8. 
134. Ait-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, et al. 
Isoniazid preventive therapy for people living with HIV: public health challenges and 
implementation issues. The international journal of tuberculosis and lung disease : the 
official journal of the International Union against Tuberculosis and Lung Disease. 
2009; 13(8): 927-35. 
135. Kabali C, von Reyn CF, Brooks DR, Waddell R, Mtei L, Bakari M, et al. Completion 
of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in 
Tanzania. The international journal of tuberculosis and lung disease : the official 
journal of the International Union against Tuberculosis and Lung Disease. 2011; 
15(11): 1515-21, i. 
136. Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C. Completion of isoniazid 
preventive therapy among HIV-infected patients in Tanzania. The international journal 
of tuberculosis and lung disease : the official journal of the International Union against 
Tuberculosis and Lung Disease. 2008; 12(9): 1037-41. 
137. Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence 
to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent 
tuberculosis in Dar es Salaam, Tanzania. BMC infectious diseases. 2015; 15: 368. 
138. Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musanhu C. 
Routine implementation of isoniazid preventive therapy in HIV-infected patients in 
seven pilot sites in Zimbabwe. Public Health Action. 2017; 7(1): 55-60. 
  55 
139. Ayele HT, van Mourik MS, Bonten MJ. Predictors of adherence to isoniazid preventive 
therapy in people living with HIV in Ethiopia. The international journal of tuberculosis 
and lung disease : the official journal of the International Union against Tuberculosis 
and Lung Disease. 2016; 20(10): 1342-7. 
140. Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, et al. Implementation and 
evaluation of an isoniazid preventive therapy pilot program among HIV-infected 
patients in Vietnam, 2008-2010. Transactions of the Royal Society of Tropical 
Medicine and Hygiene. 2015; 109(10): 653-9. 
141. LaCourse SM, Deya RW, Graham SM, Masese LN, Jaoko W, Mandaliya KN, et al. 
Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive 
Female Sex Workers in Mombasa, Kenya. Journal of acquired immune deficiency 
syndromes. 2017; 76(1): 74-81. 
142. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-
monoresistant tuberculosis in the United States, 1993 to 2003. Archives of internal 
medicine. 2008; 168(18): 1984-92. 
143. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. 
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the 
Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009; 
373(9678): 1861-73. 
144. World Health Organisation. Anti-tuberculosis drug resistance in the world: fourth 
global report (WHO/HTM/TB/2008.394). Geneva, Switzerland: WHO. 2008. 
145. Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives 
drug-resistant tuberculosis: a model-based analysis. Science translational medicine. 
2013; 5(180): 180ra49. 
146. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. 
Standardized treatment of active tuberculosis in patients with previous treatment and/or 
with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 
2009; 6(9): e1000150. 
147. Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients 
with isoniazid mono-resistant tuberculosis. Clinical microbiology and infection : the 
official publication of the European Society of Clinical Microbiology and Infectious 
Diseases. 2015; 21(1): 59-68. 
148. Nolan C, Goldberg S. Treatment of isoniazid-resistant tuberculosis with isoniazid, 
rifampin, ethambutol, and pyrazinamide for 6 months. The International Journal of 
Tuberculosis and Lung Disease. 2002; 6(11): 952-8. 
149. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-
course chemotherapy of pulmonary tuberculosis. The American review of respiratory 
disease. 1986; 133(3): 423-30. 
150. Wang TY, Lin SM, Shie SS, Chou PC, Huang CD, Chung FT, et al. Clinical 
characteristics and treatment outcomes of patients with low- and high-concentration 
isoniazid-monoresistant tuberculosis. PloS one. 2014; 9(1): e86316. 
151. Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E, et al. 
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-
Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PloS one. 2016; 11(4): 
e0152933. 
 56 
152. Yang CS. Advancing host-directed therapy for tuberculosis. Microb Cell. 2017; 4(3): 
105-7. 
153. Tomioka H, Sano C, Tatano Y. Host-Directed Therapeutics against Mycobacterial 
Infections. Curr Pharm Des. 2017; 23(18): 2644-56. 
154. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, et al. Autologous 
mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and 
extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. The Lancet 
Respiratory medicine. 2014; 2(2): 108-22. 
155. Senkoro M, Mfinanga S, Egwaga S, Mtandu R, Kamara DV, Basra D, et al. Prevalence 
of pulmonary tuberculosis in adult population of Tanzania: a national survey, 2012. The 
international journal of tuberculosis and lung disease : the official journal of the 
International Union against Tuberculosis and Lung Disease. 2016; 20(8): 1014-21. 
156. National Tuberculosis and Leprosy Program. The First National Tuberculosis 
Prevalence Survey in the United Republic of Tanzania Final Report. In: Ministry of 
Health and Social Welfare, editor. Dar es Salaam: United Republic of Tanzania; 2013. 
157. Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), 
National Bureau of Statistics (NBS), Office of the Chief Government Statistician 
(OCGS), and ICF International 2013. Tanzania HIV/AIDS and Malaria Indicator 
Survey 2011-12. Dar es Salaam, Tanzania: TACAIDS, ZAC,NBS, OCGS, and ICF 
International. 
158. National AIDS Control Program. Costing of the third Health Sector HIV and AIDS 
Strategic Plan (HSHSP III) 2013-2017. In: Ministry-Of-Health-And-Social-Welfare, 
editor. Dar es salaam: United-Republic-Of-Tanzania; 2017. 
159. Chonde TM, Basra D, Mfinanga SG, Range N, Lwilla F, Shirima RP, et al. National 
anti-tuberculosis drug resistance study in Tanzania. The international journal of 
tuberculosis and lung disease : the official journal of the International Union against 
Tuberculosis and Lung Disease. 2010; 14(8): 967-72. 
160. National Tuberculosis and Leprosy Program Xpert® MTB/RIF test Rollout and 
Implementation Plan. Dar es Salaam: Ministry Of Health And Social Welfare, United 
Republic of Tanzania. 
161. Mkopi A, Range N, Lwilla F, Egwaga S, Schulze A, Geubbels E, et al. Adherence to 
tuberculosis therapy among patients receiving home-based directly observed treatment: 
evidence from the United Republic of Tanzania. PloS one. 2012; 7(12): e51828. 
162. Egwaga S, Mkopi A, Range N, Haag-Arbenz V, Baraka A, Grewal P, et al. Patient-
centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a 
cohort study. BMC medicine. 2009; 7: 80. 
163. Yen YF, Yen MY, Lin YP, Shih HC, Li LH, Chou P, et al. Directly observed therapy 
reduces tuberculosis-specific mortality: a population-based follow-up study in Taipei, 
Taiwan. PloS one. 2013; 8(11): e79644. 
164. Mugusi SF, Ngaimisi E, Janabi MY, Mugusi FM, Minzi OM, Sasi PG, et al. Risk 
factors for mortality among HIV-positive patients with and without active tuberculosis 
in Dar es Salaam, Tanzania. Antiviral therapy. 2012; 17(2): 265-74. 
  57 
165. Bisson GP, Zetola N, Collman RG. Persistent high mortality in advanced HIV/TB 
despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. 
Curr HIV/AIDS Rep. 2015; 12(1): 107-16. 
166. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution 
inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : 
pathogenesis, clinical manifestations and management. Drugs. 2008; 68(2): 191-208. 
167. Cheng VC, Yam WC, Woo PC, Lau SK, Hung IF, Wong SP, et al. Risk factors for 
development of paradoxical response during antituberculosis therapy in HIV-negative 
patients. European journal of clinical microbiology & infectious diseases : official 
publication of the European Society of Clinical Microbiology. 2003; 22(10): 597-602. 
168. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune 
reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral 
therapy. Clin Chest Med. 2009; 30(4): 797-810. 
169. Dannenberg AM, Dey B. Perspectives for Developing New Tuberculosis Vaccines 
Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical 
Testing, and III. Clinical Testing. Vaccines. 2013; 1(1): 58-76. 
170. Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, Birch KE, Cook JE, Jackson SE, et al. 
Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to 
replicative exhaustion. Journal of immunology (Baltimore, Md : 1950). 2005; 175(12): 
8218-25. 
171. Ellertsen LK, Storla DG, Diep LM, Brokstad KA, Wiker HG, Hetland G. Allergic 
sensitisation in tuberculosis patients at the time of diagnosis and following 
chemotherapy. BMC infectious diseases. 2009; 9: 100. 
172. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G. Differential cytokine secretion 
and early treatment response in patients with pulmonary tuberculosis. Clinical and 
experimental immunology. 2009; 156(1): 69-77. 
173. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal 
tuberculosis in interleukin-6-deficient mutant mice. Infection and immunity. 1997; 
65(11): 4843-9. 
174. Tang S, Cui H, Yao L, Hao X, Shen Y, Fan L, et al. Increased cytokines response in 
patients with tuberculosis complicated with chronic obstructive pulmonary disease. 
PloS one. 2013; 8(4): e62385. 
175. Casarini M, Ameglio F, Alemanno L, Zangrilli P, Mattia P, Paone G, et al. Cytokine 
levels correlate with a radiologic score in active pulmonary tuberculosis. American 
journal of respiratory and critical care medicine. 1999; 159(1): 143-8. 
176. Ravimohan S, Tamuhla N, Steenhoff AP, Letlhogile R, Nfanyana K, Bellamy SL, et al. 
Immunological profiling of tuberculosis-associated immune reconstitution 
inflammatory syndrome and non-immune reconstitution inflammatory syndrome death 
in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a 
prospective observational cohort study. The Lancet Infectious diseases. 2015. 
177. Ravimohan S, Tamuhla N, Nfanyana K, Steenhoff AP, Letlhogile R, Frank I, et al. 
Robust reconstitution of TB-specific polyfunctional CD4+ T-cell responses and rising 
systemic IL-6 in paradoxical TB-IRIS. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America. 2015. 
 58 
178. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, Van Der 
Poll T. Serum concentrations of cytokines in patients with active tuberculosis (TB) and 
after treatment. Clinical and experimental immunology. 1999; 115(1): 110-3. 
179. Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, et al. Inflammation and 
tuberculosis: host-directed therapies. J Intern Med. 2015; 277(4): 373-87. 
180. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by 
initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000; 55(1): 
32-8. 
181. de Valliere S, Barker RD. Residual lung damage after completion of treatment for 
multidrug-resistant tuberculosis. The international journal of tuberculosis and lung 
disease : the official journal of the International Union against Tuberculosis and Lung 
Disease. 2004; 8(6): 767-71. 
182. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clinical 
cancer research : an official journal of the American Association for Cancer Research. 
2015; 21(6): 1248-57. 
183. ClinicalTrials.gov. Siltuximab therapy in clinical trials. [Electronic] 2016  [cited 2016 
11.10.2016]; Available from: 
https://clinicaltrials.gov/ct2/results?term=siltuximab&Search=Search 
184. ClinicalTrials.gov. Tocilizumab therapy in clinical trials. [Electronic] 2016  [cited 2016 
11.10.2016]; Available from: 
https://clinicaltrials.gov/ct2/results?term=tocilizumab&Search=Search 
185. Okada M, Kita Y, Kanamaru N, Hashimoto S, Uchiyama Y, Mihara M, et al. Anti-IL-6 
receptor antibody causes less promotion of tuberculosis infection than anti-TNF-alpha 
antibody in mice. Clinical & developmental immunology. 2011; 2011: 404929. 
186. Singh PP, Goyal A. Interleukin-6: a potent biomarker of mycobacterial infection. 
SpringerPlus. 2013; 2: 686. 
187. Leal IS, Smedegard B, Andersen P, Appelberg R. Interleukin-6 and interleukin-12 
participate in induction of a type 1 protective T-cell response during vaccination with a 
tuberculosis subunit vaccine. Infection and immunity. 1999; 67(11): 5747-54. 
 
 
